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 Zinc deficiency has been linked to human diseases including cancer. p53, a zinc-
containing transcription factor, is the most frequently mutated tumor suppressor protein in 
human cancer. MDM2 and MDMX are zinc- containing proteins and crucial negative 
regulators of p53, which have been found to be amplified or overexpressed in various 
cancers. To investigate the effects of zinc depletion on the p53 signaling pathway, we have 
used ion chelators TPEN and bispicen as well as zinc-deficient medium to treat cells. We 
report here that zinc depletion results in MDMX degradation in a ubiquitination-
independent and 20S proteasome-dependent manner. Restoration of zinc recovers the 
cellular levels of MDMX. Further, TPEN treatment inhibits growth of the MCF-7 cells, a 
breast cancer cell line that remains wild type p53, which is partially rescued by over- 
expression of MDMX. Moreover, we identified TRPM7, a zinc-permeable ion channel, as 
a novel MDMX- interacting protein. TRPM7 stabilizes and induces ectopic MDMX 
migration changes on SDS-PAGE. Depletion of TRPM7 attenuates while TRPM7 
overexpression facilitates the recovery of MDMX upon adding back zinc to TPEN-treated 
cells. Importantly, we found that TRPM7 inhibition, like TPEN treatment, decreases breast 
  
cancer cell MCF-7 proliferation and migration. The inhibitory effect on cell migration upon 
TRPM7 inhibition is also partially rescued by over-expression of MDMX. Together, our 
data indicate that TRPM7 regulates cellular levels of MDMX in part by modulating the 
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Chapter I. General Introduction 
 
Zinc is indispensable to living organisms 
 
Zinc is the second most abundant transition metal in living organisms (Vasak & 
Hasler, 2000). It plays a crucial role in many biochemical processes through both 
structural and catalytic functions. It has also been shown to have a direct regulatory 
role in cellular signaling pathways (Mocchegiani, Muzzioli, & Giacconi, 2000). Through 
zinc coordination proteins properly fold peptide chains, stabilize structure and 
catalyze substrates. Cysteines and histidines in proteins are usually found to 
coordinate with zinc ions to form zinc fingers, a small structural motif. Zinc fingers are 
widely found in DNA transcription factors, RNA polymerase, assembly of proteins, 
hormone receptors, and apoptosis regulators. Zinc deficiency is linked to a variety of 
human diseases including cancers such as bladder, breast, esophageal, head and neck, 
prostate, and skin cancer (Franklin & Costello, 2007). 
Genome guardian p53 
 
p53, a tumor suppressor protein encoded by TP53 gene locating on chromosome 
17 in human, got this name because of its molecular mass: 53 kDa band on SDS-PAGE. 
Normal cells have low level of p53 proteins with short half-life. Under normal 
condition, the functions of p53 proteins are strictly inhibited and p53 proteins are 
degraded through ubiquitin- proteasome pathway (Haupt, Maya, Kazaz, & Oren, 1997; 
Kubbutat, Jones, & Vousden, 1997). In response to various cellular stresses including 
DNA damage, p53 proteins are modified to avoid inhibition and degradation, and 
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obtain extended half-life (C G Maki & Howley, 1997; Maltzman & Czyzyk, 1984). 
Stabilized and activated p53 proteins mediate cellular outcomes including induction 
of cell cycle arrest, apoptosis, cellular senescence, DNA repair, and inhibition of 
angiogenesis and metastasis through both transcription-dependent and 
independent mechanisms (Meek, 2015; Vousden & Prives, 2009). 
p53 structure 
 
p53 proteins (Figure I.1) have two transcription-activation domains at N-
terminal (residues 1-67): activation domain 1 (TAD1, residues 1-42) and activation 
domain 2 (TAD2, residues 55-75). Fusion of either domain with GST could bind TATA 
binding proteins in vitro, and fusion with Gal4 proteins activates reporters to different 
level in vivo (Candau et al., 1997; Chang, Kim, Lee, Choi, & Sung, 1995). Proline rich 
domain (PR, residues 64-92) contains five PXXP copies that are required for p53-
mediated promotion of apoptosis and repression of cell growth. Deletion of proline 
rich domain fails to induce PIG3 and loses ability to produce reactive oxygen species 
(ROS) (Venot et al., 1998). This domain is also necessary for the growth arrest induced 
by Gas 1 (Ruaro et al., 1997). Central DNA-binding domain (residues 102-292) directly 
binds to DNA, which requires zinc corporation. Mutations at zinc binding site, such as 
R175H, make p53 misfold and abolish p53’s DNA binding ability, therefore prevent 
transcription of target genes. Nuclear localization signal (NLS) domain (residues 300-
323) mediates the translocation of p53 from cytoplasm into nucleus. Critical amino 
acids are needed for nuclear importation. Mutations on Lys-305 and Arg-306 cause 
less migration of p53 into nucleus (S.-H. Liang & Clarke, 1999; S. H. Liang, Hong, & 
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Clarke, 1998). Oligomerization domain (OD, residues 326-356) oligomerize p53 intro 
tetramer and is necessary for p53 binding to DNA. Mutations in this region reduce 
p53’s transcriptional activity (Kawaguchi et al., 2005). The nuclear export signal 
domain (NES) locating in tetramerization domain (residues 340-351) is highly 
conserved leucine-rich domain and mediates export of p53 from nucleus through 
association with CRM1 (Stommel et al., 1999). C-terminal regulatory domain (CTD) 
(residues 356-393) nonspecifically bind to DNA and enhances p53 transcriptional 
activity. 
 
Figure I. 1. Schematic of p53 protein structure.  p53 contains an N-terminal transactivation 
domain (TAD), which can be further divided into subdomains TAD1 and TAD2, followed by a 
proline-rich region (PRR). The DNA-binding domain and the oligomerization domain (OD) are 
connected through a flexible linker region. The regulatory C-terminal domain (CTD) is located at 
the extreme carboxyl terminus of the protein. The vertical line with dots indicates the number of 
missense-mutations in human cancer for each residue. The analysis was carried out using 
cBioPortal. The most frequently mutated residues R175, R248, and R273 were marked. (Zhu et al., 
2018) 
 
p53’s roles in arrest of cell cycle 
 
The progress of cell cycle is under the control of cyclin-dependent kinases (Cdks) 
and their regulator cyclins. Cdks have no kinase activity unless they form complex 
with cyclins. DNA damage arrests cell cycle at two checkpoints: G1/S transition and 
G2/M transition. In response to genotoxic stress as well as other stress signals, active 
p53 mediates cell cycle arrest through transcriptional activation of proteins that 
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repress cyclins and Cdks, giving cell times for DNA repair. Through binding to the 
promoter of p21 gene (a CDK inhibitor), p53 proteins activate transcription of p21 
mRNA. p21 proteins bind to cyclin E-Cdk2 and cyclin D-Cdk4 complexes and inhibit the 
phosphorylation of Retinoblastoma (Rb) induced by Cdk2 and Cdk4 (Harper, Adami, 
Wei, Keyomarsi, & Elledge, 1993). The phosphorylation status of Rb decides whether 
cells enter S phase or stay at G1 phase. Hypophosphorylated Rb binds and inhibits 
E2F transcriptional factors that activate DNA replication and genes required for S 
phase. Cdk2 and Cdk4 phosphorylate Rb so that cell cycle continues. Through 
inactivating Cdk2 and Cdk4, p21 keeps Rb dephosphorylated and blocks cell cycle 
progression. In addition to arrest G1/S, p53 also mediates arrest of cell cycle at G2/M 
transition though induction of p21 and 14-3-3σ. 14-3-3σ sequesters cyclin-B1-cdc2 
complexes that trigger cell division in cytoplasm (Chan, Hermeking, Lengauer, Kinzler, 
& Vogelstein, 1999; Hermeking et al., 1997). p21 colocalizes with cyclin A and cyclin 
B1 in nucleus, associated with inactive cyclin-Cdk complexes (Dulić, Stein, Far, & Reed, 
1998). In addition to activate genes that hold cell cycle, p53 can directly bind to 
promoters of genes that repress cell cycle. For instance, repression of cdc25C by p53 
arrest cell cycle at G2/M status (St Clair et al., 2004). 
p53’s roles in programmed cell death 
 
In response to stimuli such as DNA damage, oncogene activation and oxidative 
stress, active p53 proteins mediate programmed cell death through both 
transcription-dependent and independent mechanisms. 
Nuclear p53 activates transcription of pro-apoptotic genes such as Noxa or Puma 
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while represses transcription of anti-apoptotic genes such as Bcl2 and Survivin. 
Additionally, cytosolic pool of p53 translocates to outer membrane of mitochondria, 
where p53 inhibits anti-apoptotic factor Bcl2 and promotes oligomerization of Bax 
and Bak through DNA binding domain (Pietsch et al., 2008), resulting in pore formation 
and subsequent release of apoptotic factors. The released apoptotic factors, such as 
cytochrome c, activate caspases to cleave cellular components and finally induce 
apoptosis. Cleavage of full-length PARP (116kDa) into 89kDa and 24kDa fragments by 
caspases is an early indicator of apoptosis. The caspase-3 is proteolytically activated 
by caspase-9, which can be blocked by mutant p53 binding to procaspase-3 (Frank, 
Pietsch, Dumont, Tao, & Murphy, 2011). 
The translocation and activation of p53 are results of post-translational 
modifications. In unstressed cells, cytosolic p53 is inactivated and polyubiquitinated 
by MDM2 and then degraded in 26S proteasome. Upon DNA damage, p53 is 
phosphorylated at Ser46 by HIPK2, which triggers incorporation of Pin1 and a 
phosphorylation-dependent conformation change. This conformational change 
switches MDM2 from polyubiquitinating to multi- monoubiquitinating p53, which is 
a sign of nuclear export and mitochondrial translocation. The phosphorylated p53 on 
Ser46 after DNA damage also induces expression of proapoptotic gene p53-regulated 
Apoptosis-Inducing Protein 1 (p53AIP1) (Oda et al., 2000). p53 can also be fused to 
mitochondrial import leader peptide ornithine transcarbamylase at N-terminal, 
which targets p53 for mitochondrial translocation and reduces p53’s transactivation 
ability (Mihara et al., 2003). After arrival at mitochondria, p53 is deubiquitinated by 
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HAUSP and binds to Bcl2 and Bcl-xL proteins through DNA binding domain. Interaction 
with MDMX facilitates p53 binding to Bcl2 (Mancini et al., 2009). 
Role of p53 in cancer 
 
p53 is a major suppressor of cancer development. Lost of p53 functions is critical to 
cancer formation. Mutant p53 is founded in about 50% of human cancer. The Li-
Fraumeni Syndrome patients who have germ line p53 mutations are more likely to 
get cancer. It has been shown that viruses, such as SV40 and HPV, can inhibit p53 and 
lead to cancer (Vogelstein, Lane, & Levine, 2000). 
In human cancers that remain wild-type p53, p53’s functions are impaired, 
which weaken signaling pathways that p53 participates in. TP53 gene mutations are 
very common in human cancers and they often produce deficient p53 proteins 
(Hollstein, Sidransky, Vogelstein, & Harris, 1991; Soussi & Beroud, 2001; Vogelstein 
et al., 2000). In most of cases, mutant p53 proteins result from missense mutations 
that substitute amino acids. DNA binding domain is favored by mutations, despite 
mutations can distribute throughout TP53 gene. The ‘hotspot’ mutation sites in DNA 
binding domain concentrate on residues R175, G245, R248, R249, R273, and R282 
(Figure I.1). Mutant p53 proteins can form tetramer with wild-type p53 to inactivate 
tumor suppressor functions, when mutant and wild-type TP53 gene coexist (Milner & 
Medcalf, 1991). In addition to inactivate wild-type p53, mutant p53 may obtain 
oncogenic ability through gain-of-function (GOF) mechanism. Their GOF are proved 
by introduction of mutant p53 into p53-null cells. Mutant p53 can promote 
tumorigenesis by increasing resistance to apoptosis, elevating migration and invasion 
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of cancer cells, and disrupting genome stability. 
Although TP53 gene mutations are frequent to see, not all tumors bear TP53 
mutations  and their oncogenesis grow in pathways that impair wild-type p53. 
p53 is activated by upstream regulators through modifications in response to stress 
signals. Mutations or reduced expression of upstream regulators, such as ATM and 
Chk2, were found to reduce p53 activation. The mutations on p53’s downstream genes 
also reduce the inhibitory effect of p53. For instance, mutant p21 or 14-3-3σ fails to 
suppress cell cycle. In addition, overexpression of p53 inhibitors, including MDM2 and 
MDMX, leads to abnormal cell proliferation. 
p53 inhibitor MDM2 
 
The murine double minute 2 (MDM2) protein, a major p53 protein inhibitor, was 
cloned and identified in transformed mouse cell line 3T3-DM. The human homologue 
of this protein is also called as HDM2. MDM2’s oncogenic potential was discovered as 
its overexpression induces tumorigenicity (Fakharzadeh, Trusko, & George, 1991). 
Amplifications of MDM2 gene in human cancers are not rare cases, especially in soft 




MDM2 protein has 491 amino acids and contains three important domains 
(Figure I.2): an N-terminal domain, a central domain including an acidic domain and a 
C-4 zinc finger region, and a C-terminal Ring domain. The hydrophobic region (residues 
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1-100) in N-terminal domain (residues 1-126) enables MDM2 to interact with the 
transactivation domain of p53 and inhibit p53’s transactivation ability (Kussie et al., 
1996). The center acidic domain (AD) (residues 220- 300) and C-4 zinc finger domain 
(residues 290-335) have binding sites for many proteins that regulate MDM2’s 
functions. Multiple ribosomal proteins (L5, L11, L23, L26, L27, S3, S7, S14, S15, S20, 
S25, S26, and S27) bind to MDM2 through this region to inhibit MDM2 and activate 
p53 in response to ribosomal stress (Deisenroth et al. 2016). Binding of ARF to AD 
promotes degradation of MDM2 and stabilizes p53 (Sherr, 2006; Y. Zhang, Xiong, & 
Yarbrough, 1998). Binding of p300, a transcriptional coactivator of p53, to AD 
attenuates p300-mediated p53 acetylation and thus inhibits DNA binding and 
transcriptional activity of p53 (Grossman et al., 1998; Kobet, Zeng, Zhu, Keller, & Lu, 
2000). The C-4 zinc finger domain is a RanBP2 type zinc finger. Several cancer-
associated mutations in this region disrupt MDM2-mediated p53 ubiquitination and 
degradation and (Dai & Lu, 2004; Lindström, Jin, Deisenroth, White Wolf, & Zhang, 
2007; Y. Zhang et al., 2003). The Ring domain at C-terminal (residues 430-480) 
contains Cis3-His2-Cis3 consensus that coordinates two zinc ions (Lai, Freedman, 
Levine, & McLendon, 1998). Corporation of zinc folds Ring domain properly and 
confers MDM2-MDMX interaction. The Ring domain of MDM2 has E3 ubiquitin ligase 
activity (Fang, Jensen, Ludwig, Vousden, & Weissman, 2000). In steady cells, Ring 
domain of MDM2 ubiquitinates p53 at lysine residues and target p53 for proteasome-
dependent degradation. This ubiquitination is interfered by post-translational 
modification on p53 and MDM2 so that p53 avoids degradation and gets activation 
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(Fang et al., 2000). 
 
Figure I. 2. Domain structure of MDM2 and MDMX. MDM2 and MDMX each contains an N-
terminal p53- binding domain, a center acidic region and zinc-finger domain, as well as a C-
terminal RING finger domain. MDM2 also contains nuclear localization signal, nuclear export 
signal, and nucleolar localization signal sequences, which are not existed in MDMX. MDM2 and 
MDMX share 54% and 53% identity in their p53-binding and RING finger domain (Zhu et al., 
2018). 
 
MDM2 regulating p53 
 
MDM2 is a downstream gene of p53 and serves as negative regulator of p53. 
MDM2 can repress p53 at both ubiquitination dependent and independent manners. 
In human cancers with wild-type p53, amplification of MDM2 gene results in 
elevated MDM2 protein level and suppression of p53 (Momand, Jung, Wilczynski, & 
Niland, 1998; Oliner et al., 1992). 
MDM2 mediated ubiquitination-independent repression of p53 
 
The hydrophobic region within MDM2’s N-terminal interacts with N-terminal of 
p53 and inhibits p53’s transactivation ability (Kussie et al., 1996). Gly58, Glu68, Val75, 
and Cys77 in MDM2 are essential for p53 binding (Freedman, Epstein, Roth, & Levine, 
1997). Phe19, Trp23, and Leu26 in p53 are the most important residues for MDM2 
degradation (Böttger et al., 1997; J. Chen, Marechal, & Levine, 1993). A truncated 
MDM2, containing only N-terminal 130 amino acids, is able to reduce p53-mediated 
transactivation (Leng, Brown, Shivakumar, Deb, & Deb, 1995). MDM2 also interferes 
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acetylation or promotes deacetylation of p53 to obstruct transactivation of p53 
(Dingding Shi & Gu, 2012). CBP or its structural homology p300 bind to N-terminal of 
p53, and acetylate lysine at C-terminal of p53 and thus stimulate p53 transcriptional 
activity, while this interaction is blocked by MDM2 through binding to the N- terminal 
region of CBP/p300 (Gu & Roeder, 1997; Wadgaonkar & Collins, 1999). Through 
recruiting HDAC1, a histone deacetylase, MDM2 deacetylates p53 and reduces activity 
of p53, resulting in unstablizition of p53. This process can be reversed by mutant 
HDAC1 (Ito et al., 2002). 
MDM2 mediated ubiquitination-dependent repression of p53 
 
Ubiquitin is a small protein with molecular weight 8.6 kDa. Proteins conjugated 
with ubiquitin are usually marked for proteasome-dependent degradation. 
Conjugation of ubiquitin requires three types of enzymes: ubiquitin-activating 
enzymes (E1s), ubiquitin- conjugating enzymes (E2s), and ubiquitin ligases (E3s). E3s 
specifically transfer ubiquitin to target proteins (Pickart, 2001). An addition type of 
enzyme, E4 ubiquitin ligases (E4s), enhances elongation of ubiquitin chains induced 
by E3s on substrates (Koegl et al., 1999). MDM2’s Ring domain serves as an E3 ligase 
that mediates monoubiquitination and polyubiuitination of p53 in a ratio-dependent 
manner. High amount of MDM2 mediates polyubiquitination of p53 and nuclear 
degradation. In contrast, low amount of MDM2 induces monoubiquitination of p53 
and nuclear export (M. Li et al., 2003). CBP and p300 function as E4s to catalyze 
polyubiquitination of p53 driven by MDM2 (Grossman et al., 2003; D. Shi et al., 2009). 
E3 ligase of MDM2 is controlled by phosphorylation. c-Abl induced phosphorylation on 
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Y394, an amino acid close to Ring domain, reduces interaction between MDM2 and 
p53 to protect p53 from degradation (Goldberg et al., 2002; Sionov et al., 2001). ATM-
induced phosphorylation on S395 weakens nuclear export of p53 and slows down 
p53 degradation after DNA damage (Khosravi et al., 1999; Maya et al., 2001). 
Coordination of zinc ions are necessary for E3 ligase ability of MDM2’s Ring domain. 
Removal of zinc by TPEN treatment and mutations of zinc-binding amino acids 
abrogate p53 ubiquitination (Fang et al., 2000). 
MDM2 facilitates substrates’ interaction with proteasome subunits 
 
Proteins can be degraded by proteasomes in ubiquitin-dependent or ubiquitin-
independent way. Presence of 19S particles is not essential, but a 20S core of 
proteasome is necessary for a ubiquitin-independent degradation. MDM2 
contributes to both pathways, because MDM2 does not only ubiquitinate substrates, 
but also promotes association of substrates to proteasomes. MDM2 associates with 
subunits within 19S proteasome regulatory particles, including S2, S4a, S5a, S6a, and 
S6b, and facilitates the association of p53 with the proteasome (Kulikov et al., 2010). 
The 20S core are made up of two layers of alpha and beta subunits. In addition to 19S 
regulatory subunits, MDM2 is able to mediate retinoblastoma protein (Rb) and p21 
degradation in a ubiquitin-independent manner by facilitating the interaction of Rb 
or p21 with 20S alpha subunit 7 (Patima Sdek et al., 2005; Touitou et al., 2001). 
p53 inhibitor MDMX 
 
MDMX (murine double minute X, also known as MDM4), a homologous protein of 
MDM2, got this name because of its structural similarity to MDM2. Mouse MDMX was 
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identified earlier than human MDMX. The binding of MDMX to p53 was detected in 
vitro and in vivo (Shvarts et al., 1997; Shvarts et al., 1996). MDMX gene is 
constitutively expressed, evidenced by stable mRNA level, unlike increased MDM2 
gene expression in response to stress signals (Jackson & Berberich, 1999). MDMX 
serves as a key negative regulator of p53 that is necessary for embryogenesis. MDMX-
null mice displayed an embryonic lethality due to the loss of p53 inhibition and they 
were rescued by lose of TP53 gene (Parant et al., 2001). Aberrant expression of 
MDMX occurs in many tumors. One important difference between MDMX and 
MDM2 is that the Ring domain of MDMX, unlike MDM2, does not have E3 ligase 
ability. Therefore, MDMX cannot mediate p53 ubiquitination alone. However, 
MDMX can bind to MDM2 through their Ring domain. This Ring interaction enhances 
the efficiency of ubiquitinating p53. In contrast to MDM2, MDMX has neither nuclear 
import sequence nor nuclear export sequence. The absence of localization signal 
makes MDMX primarily localize in cytoplasm. The shuttle of MDMX into nucleus needs 
association with partners, like MDM2. 
MDMX functional regions 
 
Human MDMX protein (Figure I.2) is made up of 490 amino acids containing a 
conserved p53-binding domain at N-terminal, an acidic domain and a zinc finger 
region in the middle, and a conserved Ring domain at C-terminal. MDMX has an 
observed mass around 80kDa, more than the predicted 54kDa because of post-
translational modification. The residues 23-109 at N-terminal of MDMX form a 
complex with the residues 17-28 of p53, the transactivation domain (Popowicz, 
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Czarna, & Holak, 2008). Phosphorylation of residues at N- terminal affects binding of 
MDMX to p53. Phosphorylation of Y99 sterically block MDMX binding to p53, while 
phosphorylation of Y55 enhances binding. The central domain (residues 150-350) 
includes an acidic domain and a RanBP2 type zinc finger region. The acidic domain 
interacts with DNA binding domain of p53 and inhibits DNA binding activity of p53, 
which requires CK1α phosphorylating S289 of MDMX (L. Chen, Li, Pan, & Chen, 2005; 
Wei et al., 2016). The RanBP2 type zinc finger (residues 292-340) region suppresses 
chromosome loss and multipolar mitosis in p53-deficient cells (Matijasevic, 
Krzywicka-Racka, Sluder, Gallant, & Jones, 2016). The Ring domain of MDMX (residues 
421-490) does not have E3 ubiquitin ligase activity, unlike MDM2, but is able to stabilize 
MDM2 from ubiquitin degradation and stimulate MDM2’s E3 activity through 
formation of MDM2-MDMX heterodimer via their Ring domains, contributing to 
better efficiency of inhibition and ubiquitin-dependent degradation of p53 (Linares, 
Hengstermann, Ciechanover, Müller, & Scheffner, 2003; Sharp, Kratowicz, Sank, & 
George, 1999; Tanimura et al., 1999). The Ring domain of MDMX has a conserved 
C2H2C4 motif that coordinates two zinc ions and maintains Ring domain’s functions. 
An intact Ring domain serves as binding sites for regulatory proteins. For example, 
ARF binds to both full- length MDMX and truncated MDMX. However, in order to 
translocate MDMX into nucleus to sequester them, the Ring domain has to be present 
(Jackson, Lindstrom, & Berberich, 2001). Single amino acids within Ring domain also 
play important roles to the functions of MDMX. Substitution of cysteine 463 to alanine 
of human MDMX compromises MDM2 interaction and reduces p53 inhibition, though 
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N-terminal of MDMX retains ability to bind to p53. Mdmx C462A/C462A (a mouse 
mutation equivalent to human MDMX C463A) mice died at embryonic development 
stage due to uncontrolled p53 activation, indicating Ring domain of MDMX is 
necessary for p53 inhibition (Huang et al., 2011). 
MDMX stability in response to stress is under control of post- 
translational modifications 
 
In response to stress signals, inhibition of p53 by MDMX is rapidly relieved 
through degradation of MDMX, while MDM2 is involved in this process through 
mediating MDMX ubiquitination and targeting MDMX for ubiquitin-dependent 
proteasome degradation. Switch MDM2’s target from p53 to MDMX needs post-
translational modifications on protein p53, MDM2 and MDMX relating to 
phosphorylation, acetylation, ubiquitination et al. 
MDMX modifications follow DNA damage 
 
Ionizing radiation – induced DNA damage activates ATM (Ataxia telangiectasia 
mutated) to directly phosphorylate MDMX on S403 (Y. Pereg et al., 2005). As a primary 
signal transducer of DNA damage, ATM also activates Chk2(Checkpoint kinase 2) 
which in turn phosphorylates MDMX on S342 and S367 (L. Chen, Gilkes, Pan, Lane, & 
Chen, 2005). Phosphorylation on these serine residues, especially S367, enhances 14-
3-3 binding to MDMX, leading to translocation of MDMX into nucleus (LeBron, Chen, 
Gilkes, & Chen, 2006; Yaron Pereg et al., 2006). MDMX protein level is maintained by 
interaction with deubiquitinase HAUSP (herpes virus-associated ubiquitin specific 
protease 7) under normal condition, but this interaction is decreased upon ATM-
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dependent phosphorylation after DNA damage, contributing to MDMX degradation 
(Meulmeester et al., 2005). MDMX degradation following DNA damage is mediated by 
MDM2 in ubiquitin-dependent proteasome pathway, which requires phosphorylation 
of MDMX. Evidence shows that mutation serine367 to alanine impairs binding of 14-
3-3 to MDMX and reduces MDM2-mediated ubiquitination and degradation (Kawai 
et al., 2003; Okamoto et al., 2005). 
Following UV-C treatment, MDMX is phosphorylated at S367 by Chk1, instead of 
Chk2, which then enhances binding of 14-3-3γ to MDMX and reduces p53 
ubiquitination (Yetao Jin et al., 2006). 
DNA damage induced by genotoxic drug Doxorubicin stimulates ATM-activated 
c-Abl (Abelson non-receptor tyrosine kinase) to phosphorylate MDMX on Y99 and 
Y55, while phosphorylated Y99 impairs interaction with p53, but not Y55. This process 
is independent of S342, S367 and S403 phosphorylation (Zuckerman et al., 2009). 
MDMX is involved in responses to hypoxia 
 
Hypoxia activates p53 in an ATR-Chk1 cascade, during which Chk1 phosphorylates 
MDMX at S367, stimulating 14-3-3γ binding to MDMX. Among S342, S367 and S403, 
S367 is the most critical amino acid for 14-3-3γ binding as mutation of S367 
completely abolishes binding. In contrast to S367, mutation of S342 remains little 14-
3-3γ binding and S403 mutation does not impair interaction (Lee et al., 2012). 
MDMX regulation in response to ribosomal stress 
 
Ribosomal stress leads to activation of p53, requiring proteasome-dependent 
MDMX degradation mediated by MDM2. Ribosomal stress induced by Actinomycin 
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or low dose of 5- FU does not stimulate phosphorylation of MDMX on S367 and 14-3-
3 binding, indicating mechanisms of regulating MDMX different from DNA damage. 
Ribosomal proteins L5, L11 and L23 bind to acidic domain of MDM2 and inhibits p53 
ubiquitination, in which L11, but not L5 and L23 stimulates MDMX degradation 
(Gilkes, Chen, & Chen, 2006). Ribosomal subunit S7 stabilizes p53 through MDM2 
inhibition in a MDMX-dependent way (Zhu et al., 2009). In contrast, ubiquitination of 
MDMX by MDM2 is interrupted by non-coding 5S rRNA under non- stress conditions, 
through binding to Ring domain of MDMX (M. Li & Gu, 2011). 
Proteasome-mediated protein degradation 
 
Proteins are degraded in cells through two major ways: lysosome degradation 
and proteasome degradation. Turnover of proteins, such as transcription factors, 
regulates cellular activities, and prevents accumulation of damaged proteins. 
Proteasome-mediated ubiquitin degradation pathway has been well studies. In this 
pathway, proteins are first labeled with polypeptide ubiquitin, and then degraded by 
26S proteasome. However, it has been proven that proteasomes not only proteolyze 
ubiquitin-tagged proteins. Proteins can be degraded by proteasome independent of 
ubiquitination. In this case, unstructured region within proteins is the signal of this 
ubiquitin-independent degradation. It is difficult to distinguish ubiquitin- dependent 
and ubiquitin-independent degradation because some proteins can be degraded 
through both pathways. Furthermore, most proteasome inhibitors block both 20S 




Ubiquitin-dependent proteasome pathway 
 
Ubiquitin is a polypeptide consisting of 76 amino acids (8.6KDa). Addition of one 
ubiquitin molecule to one lysine residue of protein is monoubiquitination. 
Monoubiquitination can occur on multiple residues of proteins and affects 
localization of proteins. In many cases, monoubiquitination marks nuclear 
exportation of proteins and lysosomal degradation. Monoubiquitination is the 
prerequisite for polyubiquitination because ubiquitin chains are elongated on the first 
ubiquitin molecule (Komander, 2009). Polyubiquitinated proteins can be degraded by 
26S proteasome in cytoplasm and nucleus. 
Ubiquitination requires multiple steps. Ubiquitin-activating enzyme (E1), 
ubiquitin- conjugating enzyme (E2) and ubiquitin ligase enzyme (E3) are involved in a 
basic ubiquitination. Ubiquitin is first activated by E1 through formation thioester bond 
between E1 and ubiquitin in an ATP-dependent way. Secondly, the activated ubiquitin 
is transferred from E1 to cysteine of E2 and forms thioester bond again, which is an 
ATP-dependent process too. E3 recruits ubiquitin-conjugated E2 and specifically 
transfer ubiquitin from E2 to a lysine residue of protein substrate. The ubiquitin and 
lysine interact to each other through isopeptide bond (Hershko & Ciechanover, 1998; 
Scheffner, Nuber, & Huibregtse, 1995). An additional ubiquitin ligase (E4) enhances 
E3-mediated ubiquitin transfer and results in polyubiquitination (Koegl et al., 1999). 
The polyubiquitinated proteins are degraded by 26S proteasomes. A 26S 
proteasome consists of a 20S core and a 19S regulatory particle. Ubiquitin-tagged 
proteins are usually recognized by 19S particle, where ubiquitin chains are removed 
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by deubiquitinases. Subunits within a 19S particle drive translocation and unfolding of 
proteins through consuming ATP. Finally, unfolded proteins are degraded in the 20S 
core. 
Ubiquitin-independent proteasome pathway 
 
20S proteasomes can recognize unfolded proteins and degrade them in the 
absence of 19S particles, which does not require ubiquitination. Conformational 
changes induced by stresses lead to exposure of hydrophobic region being recognized. 
20S proteasome-mediated degradation is promoted in response to oxidation (Giulivi, 
Pacifici, & Davies, 1994; Kisselev, Kaganovich, & Goldberg, 2002). In addition to 
proteins affected by stresses, native proteins with large unstructured region that are 
considered as intrinsically disorder proteins (IDPs) are also degraded by 20S 
proteasomes. 
The 20S proteasome consists of 28 subunits that are categorized into alpha type 
and beta type. All these subunits form four layers of rings. α-type subunits constitute 
the two outer rings that determine what proteins will be proteolyzed. β-type 
subunits form the two inner rings that catalyze degradation. β1, β2 and β5 subunits 
possess caspase-like, trypsin-like and chemotrypsin-like proteolytic ability (Groll et al., 
1999). 
Proteolytic ability of 20S proteasome is regulated by binding of activators. PA200 
is a large nuclear protein (200KDa) that can bind to each end of 20S proteasome to open 
it (Ortega et al., 2005). PA28 α and β subunits are cytoplasm proteins that can also 
bind to both ends and enhances selectivity and peptidase ability. Both PA200 and 
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PA28 α, β can bind to one end of 20S and leave other end for 19S particle binding and 
form a regulator-20S-19S complex (Blickwedehl et al., 2008; Cascio, Call, Petre, Walz, 
& Goldberg, 2002). Another PA regulator PA γ stays in nucleus and upregulates 20S’s 
capacity. All these activators increase 20S’s protein degradation after oxidation 
(Pickering & Davies, 2012). Binding of regulatory proteins controls 20S proteasome 
functions. Association of NQO1 and NQO2 (NADPH: quinone oxidoreductase) with 20S 
inhibits degradation of IDPs. NQO1 and NQO2 increase in response to stress stimuli, 
including oxidation or irradiation, and stabilize proteins containing IDR, like p53 
(Asher, Tsvetkov, Kahana, & Shaul, 2005; Xu, Patrick, & Jaiswal, 2013). Association of 
substrates with 20S proteasome is specific. It has been shown that MDM2 promotes 
p21 association with 20S subunit alpha 7, which is independent of ubiquitination (Y. Jin, 
Lee, Zeng, Dai, & Lu, 2003; Touitou et al., 2001; B. Wang et al., 2010). 
TRPM7 
 
TRPM7 is a ubiquitously expressed protein that has ion channel and protein kinase 
ability. TRPM7 localizes in plasma membrane and intracellular vesicles that are 
different from endosome, lysosome and many other vesicles. These vesicles store 
zinc in normal condition and release zinc in response to oxidative stress (Sunday A. 
Abiria et al., 2017). TRPM7 shows preference of conducting Mg2+ and Ca2+, and has 
permeability to physiologically essential ions, like Zn2+, Mn2+, Co2+. Some 
environmentally toxic metals, including Ni2+, Cd2+, Ba2+ are also allowed for passing 
through (Monteilh-Zoller et al., 2003). TRPM7 consists of a N- terminal with four 
melastatin homology domains, six transmembrane segments (S1-S6) (residues 756-
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1095) and a C-terminal containing transient receptor potential (TRP) region (residues 
1109-1128), coiled-coil domain (residues 1198-1250), Serine/Threonine rich domain 
(residues 1380–1596), and the α-kinase domain (residues 1597–1821) (Figure I.3). 
The channel pore (residues 1039–1056) locates between S5 and S6. Two amino acids 
E1047 and E1052 are critical for permeability of divalent cations, especially E1047. 
E1047Q and E1052Q mutations greatly reduces permeation of divalent ions and the 
blocking of permeability is more dramatic on E1047Q (M. Li et al., 2007). TRPM7 
kinase domain can autophosphorylate serine and threonine residues in its Ser/Thr 
rich domain and phosphorylate Ser and Thr on proteins, such as histone H3, annexin 
1, myosin IIA (Clark et al., 2008; Dorovkov & Ryazanov, 2004; Ryazanova, Dorovkov, 
Ansari, & Ryazanov, 2004). TRPM7 kinase domain affects its channel activity. Mg-ATP 
binding in kinase domain inhibits TRPM7 channel. Mutation (K1648R) that abolishes 
ATP binding in the kinase domain reduces inhibition of channel function (Demeuse, 
Penner, & Fleig, 2006). In addition to affect channel domain, the C-terminal kinase 
domain of TRPM7 can be cleaved in a cell-type specific manner and translocate to 
nucleus, where it can bind multiple components of chromatin remodeling complexes 
as well as several transcription factors containing zinc-binding domains. Binding to 
those zinc-finger containing proteins requires zinc (Krapivinsky, Krapivinsky, 
Manasian, & Clapham, 2014). 
TRPM7 play roles in cell growth, proliferation, differentiation, survival through 
sensing stimuli in or out of cells, conducting cation flux, influencing transcription et 
al. Silencing of TRPM7 reduces cell growth. Abnormal TRPM7 expression is present in 
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various type of carcinomas and TRPM7 correlates with migration, invasion in cancer 
cells. Overexpression of TRPM7 was found in breast cancer and led to larger tumor 
size (Guilbert et al., 2009). Chemicals that can modulate TRPM7 activities have 
been identified and used to study mechanisms of TRPM7 in cells. 
 
 
Figure I. 3. A schematic diagram to illustrate the protein structure of TRPM7 channel-kinase. 




Chapter II. The ion channel TRPM7 regulates 




Zinc deficiency has been linked to human diseases including cancer. MDMX, a 
zinc- containing protein and crucial negative regulator of p53, has been found to be 
amplified or overexpressed in various cancers. We report here that zinc depletion by 
the ion chelator TPEN or Chelex resin results in MDMX degradation in a ubiquitination-
independent and 20S proteasome-dependent manner. Restoration of zinc recovers 
the cellular levels of MDMX. Further, TPEN treatment inhibits growth of the MCF-7 
breast cancer cell line, which is partially rescued by over-expression of MDMX. 
Moreover, we identified TRPM7, a zinc-permeable ion channel, as a novel MDMX-
interacting protein. TRPM7 stabilizes and induces ectopic MDMX migration changes 
on SDS-PAGE. Depletion of TRPM7 attenuates while TRPM7 overexpression facilitates 
the recovery of MDMX upon adding back zinc to TPEN-treated cells. Importantly, we 
found that TRPM7 inhibition, like TPEN treatment, decreases breast cancer cell MCF-
7 proliferation and migration. The inhibitory effect on cell migration upon TRPM7 
inhibition is also partially rescued by over-expression of MDMX. Together, our data 
indicate that TRPM7 regulates cellular levels of MDMX in part by modulating the 





Zinc is the second most abundant transition metal in living organisms (Vasak & 
Hasler, 2000). It plays a crucial role in many biochemical processes through both 
structural and catalytic functions. It has also been shown to have a direct regulatory 
role in cellular signaling pathways (Mocchegiani et al., 2000). Zinc deficiency is linked 
to a variety of human cancers such as bladder, breast, esophageal, head and neck, 
prostate, and skin cancer (Franklin & Costello, 2007). 
p53, a zinc-containing transcription factor, is the most frequently mutated 
tumor suppressor protein in human cancer (Vogelstein et al., 2000). The role of zinc 
in stabilizing wild-type p53 structure and loss of bound zinc in cancer derived mutant 
p53 proteins has been well documented (Y. Cho, Gorina, Jeffrey, & Pavletich, 1994; 
Stoner et al., 2009; Warren et al., 2013; X. Yu, Vazquez, Levine, & Carpizo, 2012). Two 
crucial negative regulators of p53, the homologous proteins, MDM2 and MDMX, are 
also zinc-containing proteins. Each has a C4 zinc-finger domain in their central region 
and a RING-type zinc finger domain at their C- terminus (Wade, Li, & Wahl, 2013). 
The C-terminal RING domain of MDM2 but not MDMX possesses an intrinsic E3 
ubiquitin ligase activity and MDMX regulates MDM2 E3 ligase activity through RING-
RING interactions (Kawai, Lopez-Pajares, Kim, Wiederschain, & Yuan, 2007). Through 
the RING-containing E3 ligase activity, MDM2 promotes ubiquitination and 26S 
proteasome-mediated degradation of both p53 and MDMX in addition to several 
other cellular proteins (Marine & Lozano, 2010). Zinc chelation or RING finger 
mutations abolish the E3 ligase activity of MDM2 (Fang et al., 2000). Moreover, it 
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has been reported that MDM2 facilitates p21(Y. Jin et al., 2003; Z. Zhang et al., 2004) 
or Rb (P. Sdek et al., 2005) degradation through its binding to the C8 alpha subunit of 
the 20S proteasome independent of its E3 ligase function. The central region of 
MDM2 contains a C4 zinc-finger domain that has been shown to interact with 
multiple MDM2 regulatory proteins (Fahraeus & Olivares-Illana, 2014; Manfredi, 
2010). Several cancer-associated mutations have been identified in the MDM2 C4 
zinc-finger domain to disrupt the MDM2-ribosomal protein interaction and attenuate 
MDM2- mediated p53 degradation (Lindstrom, Jin, Deisenroth, White Wolf, & 
Zhang, 2007). The MDMX RING domain can repress the proliferation of p53-null 
cells, while the zinc-finger domain of MDMX suppresses genome instability and 
tumor growth (Matijasevic et al., 2016). 
The TRPM7 (transient receptor potential melastatin 7) is a bifunctional protein 
with both ion channel and α-type protein kinase feature (Runnels, Yue, & Clapham, 
2001). TRPM7 is required for early embryonic development (J. Jin et al., 2008; J. 
Jin et al., 2012) and is abnormally overexpressed in various cancer cells (Yee, 
2017). As a cation channel, TRPM7 conducts physiologically essential metal cations 
such as Zn2+, Mg2+, and Ca2+ as well as environmentally toxic metals such as Ni2+, 
Cd2+, and Ba2+ with particularly high permeation of Zn2+ (Monteilh-Zoller et al., 2003). 
The C-terminal kinase domain of TRPM7 can be cleaved and translocated to the 
nucleus, where it can bind multiple components of chromatin remodeling complexes 
as well as several transcription factors with zinc-binding domains (Desai et al., 
2012; Krapivinsky et al., 2014). It has been hypothesized that TRPM7-mediated 
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modulation of intracellular Zn2+ concentration leads to epigenetic chromatin 
covalent modifications that affect gene expression patterns (S. A. Abiria et al., 2017; 
Desai et al., 2012). Here, we report that zinc depletion results in MDMX degradation 
in a ubiquitination-independent and 20S proteasome-dependent manner. Adding 
back zinc recovers the cellular levels of MDMX while depletion of TRPM7 attenuates 
the effects of zinc. In addition, we show that TRPM7 interacts with and induces 
changed migration of the MDMX polypeptide upon denaturing polyacrylamide gel 
electrophoresis (SDS-PAGE) that require the TRPM7 channel function. Moreover, 
TRPM7 inhibition decreases MCF-7 cancer cell growth and migration, while MCF-7 
cells with MDMX over-expression are more resistant to TRPM7 inhibition- mediated 
cell migration suppression. Together, our results indicate that TRPM7 regulates 
cellular levels of MDMX in part by modulating intracellular zinc concentration, which 





Zinc depletion by TPEN reduces cellular levels of MDMX 
 
In order to investigate the effects of zinc on the p53 signaling pathway, MCF-7 
breast cancer cells were treated with 5 µM TPEN, an intracellular membrane-
permeable zinc chelator. As shown in Figure II.1A, we found that TPEN treatment 
induces p53 as previously reported (Ra, Kim, Lee, & Kim, 2009). Intriguingly, the 
cellular levels of MDMX were dramatically reduced while the levels of MDM2 were 
simultaneously increased. Similarly, when we treated MCF-7 cells with bispicen, 
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another zinc chelator, we observed induction of p53 and MDM2 levels but reduction 
of MDMX levels (Figure II.1B). MDMX reduction was also observed in cells grown in 
zinc-deficient DMEM medium in comparison to the cells that were grown in zinc- 
deficient DMEM supplemented with 5 µM ZnSO4, or regular DMEM medium (Figure 
II.1C). Note that under this condition no p53 or MDM2 induction was observed. This 
may be due to the fact that TPEN and bispicen are membrane-permeable agents 
which can deplete intracellular zinc more efficiently than the extracellular zinc-
deficient medium (Y. E. Cho et al., 2007). TPEN and bispicen may also activate p53 
through other mechanism(s). Nevertheless, our results demonstrate that cellular 
levels of MDMX are sensitive to zinc depletion. The reduction of MDMX levels 
most likely happen post-transcriptionally. Quantitative-RT-PCR analysis revealed 
that mRNA levels of MDMX remained fairly constant during the time period of TPEN 
treatment (Figure II.1D). Furthermore, we found that the levels of ectopically 
expressed MDMX proteins in HEK293T cells also decrease upon TPEN treatment 
(Figure II.1E).  
To show that the effects of TPEN on cellular levels of MDM2, MDMX, and p53 are 
due to zinc depletion but not other divalent cations, we pre-treated MCF-7 cells with 5 
µM TPEN and added back 25 µM ZnSO4, CaCl2, or MgCl2. As shown in Figure 1F, adding 
back Zn2+ but not Ca2+ or Mg2+ reversed the effect of TPEN, as MDMX degradation was 
attenuated and the levels of p53 and MDM2 were decreased and went back to the 
same levels as in untreated cells. Similarly, adding back Zn2+ also reversed the effects 
of bispicen on cellular levels of MDMX, MDM2, and p53 (Figure II.S1A). 
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The effect of TPEN was not limited to MCF-7 cells. As shown in Figure II.S1B, 
TPEN treatment led to reduced cellular levels of MDMX but increased levels of MDM2 
and p53 in LNCaP prostate cancer cells. In PC3 cells, another p53-null prostate cancer 
cell line, we also observed TPEN-induced MDMX degradation. Together, our data 
demonstrate that zinc depletion has distinct effects on the three key components of 
the p53 signaling pathway. Most importantly, our results show that zinc depletion 






Figure II. 1. Zinc depletion represses MDMX at protein level. (A) TPEN reduces cellular levels 
of MDMX but increases MDM2 and p53. MCF-7 cells were treated with DMSO (control) or 5 µM 
TPEN and harvested at indicated time points. (B) Bispicen reduces cellular levels of MDMX. 
MCF-7 cells were treated with 5 µM TPEN or increasing dosages of Bispicen (10, 50, or 100 µM) 
for 8 hours. (C) Zinc depletion by Chelex resin reduces cellular levels of MDMX. MCF-7 cells 
were incubated in DMEM with 10% of normal FBS, DMEM with 10% of Chelex resin-treated 
FBS, or DMEM with 10% of Chelex resin-treated FBS supplemented with 5 µM ZnSO4 for two 
days. (D) mRNA levels of MDMX remain constant after TPEN treatment. MCF-7 cells were 
treated and harvested as in panel A. Total RNA was extracted. Quantitative RT-PCR was carried 
out to check mRNA levels of MDMX. (E) TPEN reduces levels of ectopically expressed MDMX. 
HEK293T cells were transfected with increasing amounts of Myc-MDMX plasmids (0.15, 0.25, or 
0.5 µg). GFP plasmids (0.05 µg) were also included as transfection control. Twenty-four hours 
after transfection, the transfected cells were treated with 5uM TPEN for 8 hours. (F) Adding back 
Zn2+ but not Ca2+, Mg2+ reverses the effect of TPEN on the cellular levels of MDMX, MDM2 
and p53. MCF-7 cells were treated with 5 µM of TPEN for 5 hours and then 25 µM CaCl2, MgCl2, 
















Figure II.S 1. Zinc depletion reduces cellular levels of MDMX. (A) Adding back Zn2+ reverses 
the effect of bispicen on cellular levels of MDMX, MDM2 and p53. MCF-7 cells were treated with 
100 µM bispicen for 5 hour then 5 or 25 µM ZnSO4 were added. Five hours later, the cells were 
harvested and total cell lysates were analyzed by immunoblotting with indicated antibodies. (B) 
TPEN reduces cellular levels of MDMX in prostate cancer cells. LNCaP and PC3 cells were treated 
with 5 µM TPEN alone or in combination with 25 µM MG132 for 5 hours. The cells were harvested 
and total cell lysates were analyzed by immunoblotting with indicated antibodies. 
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TPEN-induced MDMX degradation is mediated by proteasome 
 
TPEN-mediated zinc chelation can cause oxidative DNA damage and chromosome 
breaks (Ho, Courtemanche, & Ames, 2003) and activate cytosolic caspase activity 
(Hashemi, Ghavami, Eshraghi, Booy, & Los, 2007). It has been shown that proteasome-
mediated degradation of MDMX occurs after DNA damage or ribosomal stress (de 
Polo, Vivekanandan, Little, & Yuan, 2016). In addition, it was reported that MDMX can 
be subjected to caspase cleavage at Glu361, leading to reduced cellular MDMX levels 
(Gentiletti et al., 2002). Moreover, zinc chelation may lead to MDMX misfolding for 
lysosomal degradation. To examine the mechanism(s) that account for TPEN-induced 
MDMX reduction, we pre-treated MCF-7 cells with 5 µM TPEN, and then co-treated 
cells with the proteasome inhibitor MG-132, or two types of lysosome inhibitor 
chloroquine and bafilomycin A1. We found that only MG-132 but not chloroquine or 
bafilomycin A1 reversed the effect of TPEN on MDMX, suggesting that TPEN-induced 
MDMX degradation is mediated by the proteasome but not by lysosomal-mediated 
turnover (Figure II.2A). Similarly, in LNCaP cells, MG-132 but not chloroquine or 
bafilomycin A1 co-treatment reversed the effect of TPEN on cellular levels of MDMX 
(Figure II.S2A). Note that both chloroquine and bafilomycin A1 inhibited LC3B-II 
degradation (Figure II.S2A), indicating their effectiveness under the experimental 
condition. 
To test if caspase cleavage accounts for TPEN-mediated MDMX reduction, MCF-
7 cells were treated with 5 µM TPEN in the presence or absence of the caspase 
inhibitor Z-VAD-FMK. We found that TPEN treatment led to reduced-levels of MDMX 
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regardless of the presence of Z-VAD-FMK (Figure II.2B). Similarly, Z-VAD-FMK had 
no effect on TPEN-induced MDMX reduction but inhibited TPEN-induced PARP 
cleavage in LNCaP cells (Figure II.S2A). Additionally, we observed that TPEN 
treatment reduces the cellular levels of ectopically expressed wild-type MDMX as 
well as the mutant MDMX (D361A), a mutant that is resistant to caspase cleavage 
(Figure II.2C). Note that we detected a slight increase in ROS (Reactive Oxygen 
Species) levels in TPEN treated cells in comparison to the DMSO treated cells, but to 
a much lesser extent when compare to cells treated with pyocyanin, a cell-
permeable compound capable of redox cycling (Figure II.S2B). Therefore, under our 
experimental conditions, caspase cleavage most likely does not contribute to TPEN-











Figure II. 2. TPEN-induced MDMX degradation is mediated by proteasome but not lysosome 
or caspase cleavage. (A) Proteasome inhibitor MG-132 but not lysosome inhibitors protect 
MDMX from degradation. MCF-7 cells were treated with DMSO (control) or 5 µM TPEN for 3 
hours and then MG-132 (25 µM), chloroquine (CQ: 25, 50, or 100 µM) or bafilomycin A1(A1; 50, 
100, or 500 nM) were added and incubated for another 5 hours. (B) Caspase inhibitor does not 
prevent MDMX from TPEN-induced degradation. MCF- 7 cells were treated with 5 µM TPEN in 
the presence or absence of Z-VAD-FMK (25 µM) for 8 hours. (C) TPEN reduces levels of 
ectopically expressed MDMX caspase cleavage-resistant variant D361A. HEK293T cells were 
transfected with wild-type Myc-MDMX or Myc-MDMX D361A (0.15 µg). Twenty-four hours 










Figure II.S 2. TPEN treatment induces minimal ROS in MCF7 cells and mediates MDMX 
degradation through proteasome. (A) TPEN-induced MDMX degradation is mediated by 
proteasome. LNCaP cells were treated with DMSO or TPEN (5 µM) for 3 hours then MG-132 (25 
µM), Z-VAD-FMK (25 µM), chloroquine (CQ: 50 µM) or bafilomycin A1(A1; 10 nM) were added. 
Five hours later, the cells were harvested and total cell lysates were analyzed by immunoblotting 
with indicated antibodies. (B) TPEN treatment induces minimal ROS production. 2.2 ×104 MCF7 
cells per well were plated on 96-well plates in triplicates for 5 experimental groups. Eighteen hours 
later, two sets of triplicate cells were treated with DMSO or TPEN (5 µM) for 8 hours and cellular 
ROS levels were measured using ROS Detection Cell-Based Assay Kit (DCFDA). Positive control 
(pyocyanin treatment), negative control (N-actyl cysteine treatment), and no treatment control were 
also included in triplicates following the manufacture’s procedure. Total DCFDA (2,7- 
Dichlorofluoroscin Diacetate) fluorescence was measured using an excitation wavelength at 480 
nm and emission wavelength at 530 nm. 
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TPEN-induced MDMX degradation is mediated by 20S 
proteasome, independent of ubiquitination and MDM2 
 
MDMX degradation is controlled in part by MDM2-mediated ubiquitination and 
proteasome degradation (Wade et al., 2013). To examine whether TPEN induces 
MDMX ubiquitination, we found that while MG132 treatment led to the 
accumulation of ubiquitinated MDMX species, no such accumulation was observed 
in the presence of TPEN, indicating a ubiquitin-independent mechanism (Figure II.3A). 
MDM2-mediated p53 ubiquitination was analyzed at the same time to confirm that 
the assay worked under the experimental conditions. In line with this observation, 
we found that two E3 ligase inhibitors of MDM2 [HLI373 (Kitagaki, Agama, Pommier, 
Yang, & Weissman, 2008) and compound 1 (S. Yu et al., 2009)] cannot rescue the 
effect of TPEN on cellular levels of MDMX (Figure II.S3A). This is consistent with 
previous report showing that zinc chelation by TPEN abolishes the E3 ligase function 
of MDM2 (Fang et al., 2000). 
As the 20S proteasome has been shown to degrade proteins that contain 
unstructured regions by a ubiquitin-independent mechanism (Ben-Nissan & Sharon, 
2014), we speculated that zinc depletion could lead to MDMX misfolding, resulting 
in its 20S but not 26S proteasome -mediated degradation. To test this possibility, we 
co-treated MCF-7 cells with 5 µM TPEN along with an increased dosage of capzimin 
dimer, an inhibitor of the 19S proteasome cap subunit Rpn11. The capzimin dimer did 
not prevent MDMX from degradation, suggesting that 26S proteasome function is not 
required for MDMX degradation (Figure II.3B). Furthermore, in MCF-7 cells 
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transfected with siRNAs targeting the 19S proteasome cap subunits PMSC2 
(ATPase 2) and PSMD1 (non-ATPase regulatory subunit; a.k.a. Rpn2), TPEN induced 
MDMX degradation similarly as in cells transfected with control siRNA (Figure II.3C). 
Note that cellular levels of p53 were elevated upon inhibition of 26S proteasome 
function as previously reported (C. G. Maki, Huibregtse, & Howley, 1996). Together, 
our results demonstrate that in the presence of TPEN, MDMX is targeted for 20S 
proteasome-mediated degradation in a ubiquitination-independent manner. 
As MDM2 has been found to associate with several subunits of the 19S 
proteasome regulatory particle and target p53, p21 and Rb for proteasome-
dependent but ubiquitination- independent degradation, we assumed that the 
accumulated MDM2 upon TPEN treatment would still somehow facilitate the 
degradation of MDMX. Accordingly, we transfected MCF-7 cells with control siRNA or 
two different siRNAs which targets MDM2. Remarkably, TPEN induced MDMX 
degradation in cells treated with the MDM2 siRNAs to a similar extent as in cells 
treated with control siRNA (Figure II.3D). Similarly, TPEN induced MDMX degradation 
to a similar extent in MCF-7 cells with or without pre-treatment of MD-224, an MDM2 
PROTAC degrader (Y. Li et al., 2019) (Figure II.S3B). Note that MD-224 failed to 
degrade MDM2 but induced cellular levels of p53 in MCF-7 cells. In 22RV1 cells, a 
prostate cancer cell line that MD-224 did degrade MDM2 under our experimental 
condition, TPEN induced MDMX degradation with or without MD-224 treatment 
(Figure II.S3C). Therefore, our data indicate that MDM2 is not required for TPEN-





Figure II. 3. TPEN-induced MDMX degradation is mediated by 20S proteasome, 
independent of ubiquitination and MDM2. (A) TPEN does not induce ubiquitination of MDMX. 
HEK293T cells were transfected with combination of Myc-MDMX (1 µg), HA-p53 (1 µg), and 
His-ubiquitin (2.5 µg) plasmids as indicated. GFP plasmids (0.1 µg) were also included as 
transfection control. Twenty-four hours later, cells were treated with or without 5 μM TPEN for 3 
hours and then 25 μM MG-132 was added and incubated for 5 hours. Total cell lysates were 
prepared with 1/10 of the cell lysates saved as input control. The rest were subjected to Ni-NTA-
agarose beads pull-down. Both input and eluted proteins were analyzed by immunoblotting with 
indicated antibodies. (B) Inhibition of 19S proteasome cap subunit Rpn11 does not prevent MDMX 
from degradation. MCF-7 cells were treated with 5 µM TPEN in the absence or presence of 
capzimin dimer (2.5, 5, 10, or 20 μM), or capzimin dimer only (5 μM) for 8 hours. (C) Knock-
down 19S proteasome cap subunit Rpn2 does not prevent MDMX from degradation. MCF-7 cells 
were transfected with siRNAs targeting Rpn2 (siRpn2_1 and siRpn2_2). Forty-eight hours after 
transfection, the cells were treated with 5 µM TPEN for 5 hours. Then ZnSO4 (5 µM) was added 
as indicated for 5 hours. (D) Depletion of MDM2 by siRNAs does not prevent TPEN-mediated 
MDMX degradation. MCF-7 cells were transfected with two different siRNAs targeting MDM2 
(siMDM2_1 and siMDM2_2). Forty-eight hours later, the cells were incubated with 5 µM TPEN 













Figure II.S 3. TPEN-induced MDMX degradation is independent of MDM2. (A) MDM2 
inhibitors does not protect MDMX from TPEN-induced degradation. MCF-7 cells were treated 
with DMSO (control) and 5 µM TPEN for 5 hours and then ZnSO4 (25 µM), compound 1 (Comp1: 
6, 12, or 24 µM), or HLI373 (5 or 10 µM) was added as indicated. Five hours later, the cells were 
harvested and total cell lysates were analyzed by immunoblotting with indicated antibodies. (B-C) 
MDM2 PROTAC degrader MD-224 does not protect MDMX from TPEN-induced degradation. 
MCF-7 cells (B) or 22Rv1 cells (C) were pre-treated with DMSO (control) and 30 nM MD-224 for 
2 hours. Both sets of cells were then treated with DMSO (control) or 5 µM TPEN for 5 hours. For 
MCF-7 cells, 25 µM ZnSO4 was added back in one set of TPEN treated cells as indicated. Five 




TPEN-induced MDMX reduction does not require MDMX 
phosphorylation at key serine residues 
 
Stress-induced MDMX phosphorylation at several residues in its central domain 
has been shown to mediate MDMX nuclear translocation and subsequent 
degradation (de Polo et al., 2016). We considered that phosphorylation events are 
needed for TPEN-mediated MDMX degradation and transfected HEK293T cells with 
different MDMX variants harboring mutation at Ser347, Ser367, or Ser403. 
Phosphorylation on these serine residues has been shown to be critical for DNA 
damage-induced MDMX degradation (de Polo et al., 2016). As shown in Figure II.4A, 
the mutant MDMX proteins were as sensitive to TPEN treatment as wild-type MDMX. 
Moreover, the MDMX protein carrying mutation at all these three residues was more 
resistant to etoposide or doxorubicin than TPEN treatment (Figure II.4B). Furthermore, 
using U2OS cell clones that express mutant MDMX (S367L) from the endogenous 
MDMX locus, we found that endogenous MDMX S367L is more resistant to etoposide 
than TPEN treatment (Figure II.4C). In line with these results, TPEN treatment 
induced cellular levels of phosphorylated H2AX, a marker for DNA double-strand 
breaks, although to a much lesser extent in comparison to etoposide, a 
topoisomerase II inhibitor and chemotherapeutic agent (Figure II.S4).Therefore, DNA 
damage-induced MDMX phosphorylation may not be involved in TPEN-mediated 
MDMX degradation. Nevertheless, we cannot rule out that phosphorylation at other 











Figure II. 4. TPEN-induced MDMX reduction does not require MDMX phosphorylation at 
Ser342, Ser367, or Ser 403. (A) TPEN induces degradation of ectopically expressed MDMX 
variants S342A, S367L, or S403A. HEK293T cells were transfected with 0.15 µg of wild-type 
Myc-MDMX or Myc-MDMX variants S342A, S367L, or S403A. Twenty-four hours after 
transfection, the cells were treated with 5 µM TPEN for 8 hours. (B) MDMX mutant 
(S342AS367LS403A) is more resistant to etoposide or doxorubicin than TPEN treatment. MCF-7 
cells in 60-mm dishes were transfected with 0.75 µg of wild-type Myc-MDMX or Myc-MDMX 
mutant (S342AS367LS403A). Six hours after transfection, the cells were trypsinized and plated 
into four 35-mm dishes. After 18 hours, the cells were treated with DMSO, TPEN (5 µM), 
etoposide (20 µM), or doxorubicin (10 µM) for 8 hours. (C) TPEN induces endogenous MDMX 
S367L degradation. U2OS cells with endogenous MDMX S367L mutation were treated with TPEN 




















Figure II.S 4. TPEN induces DNA damage to a much lesser extent than etoposide. MCF-7 
cells were treated with DMSO, 5 µM TPEN, or 15 µM etoposide for 8 hours. In one set of the 
TPEN treated cells, 25 µM ZnSO4 was added back 3 hours after TPEN treatment and the cells 
were incubated for another 5 hours. Total cell lysates were then prepared and subjected to 
immunoblotting with anti-γH2AX or anti-actin antibodies. 
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The ion channel protein TRPM7 interacts with MDMX and 
regulates zinc depletion-induced MDMX degradation 
 
In a mass spectrometry-based proteomics analysis, we identified TRPM7, an ion 
channel protein, as a potential MDM2/MDMX heterodimer interacting protein 
(Figure II.S5A). Using co-immunoprecipitation assay with ectopically expressed 
proteins we confirmed its interaction with MDMX but not MDM2 (Figure II.S5B 
and II.S5C). Intriguingly, when we ectopically expressed TRPM7 with MDMX in the 
presence or the absence of MDM2, we found that TRPM7 co-expression stabilized 
MDMX and induced a change in MDMX migration on SDS- PAGE (Figure II.5A). Since 
TRPM7 is a bifunctional protein with both ion channel and α-type kinase function 
(Runnels et al., 2001), we introduced either a channel-defective mutation E1047Q 
(M. Li et al., 2007) or a kinase-dead mutation K1646R (Schmitz et al., 2003) into 
TRPM7 and examined its effect on co-transfected MDMX. As shown in Figure 5B, the 
TRPM7 E1047Q but not the TRPM7 K1646R was unable to stabilize MDMX or induce 
altered MDMX migration on SDS-PAGE. Moreover, NS8593, a specific TRPM7 channel 
inhibitor (Chubanov, Schafer, Ferioli, & Gudermann, 2014), counteracted the effects of 
wild-type TRPM7 on MDMX stability and migration (Figure II.5C). Together, our results 
reveal that the channel function of TRPM7 is critical for TRPM7-induced MDMX 
stabilization and migration change on SDS-PAGE. 
To further test if TRPM7 is involved in TPEN-mediated MDMX degradation, MCF-
7 cells were transfected with control siRNA or two different siRNAs that targets 
TRPM7. Forty-eight hours later, cells were pre-treated with 5 µM TPEN and then 5 µM 
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ZnSO4 was added. As shown in Figure 5D, Zn2+-mediated recovery of MDMX in the 
presence of TPEN is attenuated upon the depletion of TRPM7. In line with this data, 
NS8593 attenuated the effect of Zn2+ on TPEN-induced MDMX degradation (Figure 
II.5E). On the other hand, we found that in TPEN-treated HEK293T cells, 
overexpression of TRPM7 facilitates the Zn2+-mediated recovery of MDMX (Figure 
II.5F). Therefore, TRPM7 is likely involved in Zn2+-mediated recovery of MDMX in 







Figure II. 5. The ion channel protein TRPM7 stabilizes ectopically expressed MDMX, induces 
ectopic MDMX migration changes on SDS-PAGE, and regulates TPEN-induced MDMX 
degradation through its channel function. (A) TRPM7 stabilizes ectopically expressed MDMX 
and induces ectopic MDMX migration changes on SDS-PAGE. HEK293T cells were transfected 
with combination of Myc-MDMX (0.15 µg), Flag- MDM2 (1 µg), and Flag-TRPM7 (1 µg) as 
indicated. Total cell lysates were analyzed 24 hours after transfection. (B) Channel but not kinase 
function of TRPM7 is needed for TRPM7-induced MDMX migration change. HEK293T cells were 
transfected with Myc-MDMX (0.2 µg) and different Flag-TRPM7 variants (1 µg; wild-type, 
E1027Q or K1646R) as indicated for 24 hours. (C) TRPM7 channel inhibitor NS8593 counteracts 
the effect of wild-type TRPM7 on MDMX stability and migration change. HEK293T cells were 
transfected with Myc-MDMX (0.2 µg) and different Flag-TRPM7 variants (1 µg; wild-type, 
E1027Q or K1646R) as indicated. Twenty-four hours after transfection, DMSO or NS8593 (2 or 
10 µM) was added and cells were incubated for another 12 hours before harvesting. (D) 
Knockdown TRPM7 by siRNAs attenuates Zn2+- mediated recovery of MDMX in the presence 
of TPEN. MCF-7 cells were treated with control siRNA or two different siRNAs targeting TRPM7 
(siTRPM7-1 and siTRPM7-2). Forty-eight hours later, the cells were treated with 5 µM TPEN for 
5 hours and then incubated with or without 5 µM ZnSO4 for another 5 hours. (E) TRPM7 channel 
inhibitor NS8593 attenuates Zn2+-mediated recovery of MDMX in TPEN-treated MCF-7 cells. 
MCF-7 cells were treated with 5 µM TPEN for 5 hours and then 5 µM ZnSO4 were added in the 
absence of presence of 50 µM NS8593. The cells were harvested at 1, 3 or 5 hours after ZnSO4 
and NS8593 treatment. (F) Overexpression of TRPM7 facilitates Zn2+-mediated recovery of 
MDMX in TPEN-treated HEK293T cells. HEK293T cells were plated in 60 mm dishes and 
transfected with Flag-TRPM7 variants (2 µg). Twenty-four hours after transfection, cells were 
trypsinized and re-plated into three 35 mm dishes. Twenty- four hours after re-plating, the cells 
were treated with DMSO, 4 µM, or 5 µM TPEN for 5 hours. Then 5 µM ZnSO4 was added into 
one of TPEN-treated dish. One hour later, the cells were harvested and total cell lysates were 










Figure II.S 5. TRPM7 interacts with MDMX. (A) TRPM7 was identified as a potential binding 
protein for MDM2/MDMX heterodimer. Twenty plates (150 mm) of HEK293T cells were each 
transfected with Flag- MDM2 (10 µg) or Flag-MDM2 (10 µg) plus Myc-MDMX (3 µg). Total cell 
lysates were prepared and subjected to immunoprecipitation with anti-Flag antibody. The co-
immunoprecipitated proteins were analyzed by SDS-PAGE followed by silver staining. 
Differentially pulled-down protein bands were excised from the gel and subjected to mass-
spectrometry analysis. Here, one protein in band 4 from co-immunoprecipitation samples of Flag-
MDM2 plus Myc-MDMX co-transfected cells was identified as TRPM7. (B and C) TRPM7 
interacts with MDMX. In Panel B, HEK293T cells were transfected with Flag-TRPM7 (1 µg), 
Myc-MDMX (0.3 µg) or in combination as indicated. Twenty-four after transfection, cells were 
harvested and total cell lysates were prepared and subjected to immunoprecipitation with anti-Flag 
antibody. The co-immunoprecipitated proteins were analyzed by immunoblotting with anti-Flag or 
anti-MDMX antibodies. In Panel C, HEK293T cells were transfected with Flag-TRPM7 (1 µg), 
Flag-MDM2 (1 µg), Myc-MDMX (0.3 µg) or in combination as indicated. Twenty-four after 
transfection, cells were harvested and total cell lysates were prepared and subjected to 
immunoprecipitation with anti-Myc antibody. The co-immunoprecipitated proteins were analyzed 
by immunoblotting with anti-Flag or anti-MDMX antibodies. 
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MDMX overexpression partially rescues the inhibitory effect of 
TPEN on cancer cell growth and the inhibitory effect of TRPM7 
depletion on cancer cell migration 
 
TPEN treatment inhibited MCF-7 cell growth on a colony formation assay, 
whereas the addition of zinc completely abolished the inhibitory effect of TPEN 
(Figure II.6A). TPEN treatment also repressed MCF-7 cell growth in a cell proliferation 
assay (Figure II.6B). NSC207895, an MDMX inhibitor that blocks the MDMX promoter 
and inhibits the MDMX expression (H. Wang, Ma, Ren, Buolamwini, & Yan, 2011), 
enhanced the inhibitory effect of TPEN on MCF-7 cell proliferation (Figure II.6B and 
Figure II.S6A). Similar results were obtained using MCF-7 cells treated with control 
siRNA or siRNA targeting MDMX in the absence or presence of TPEN (Figure II.S6B). 
On the other hand, using MCF-7 cells with tetracycline- inducible MDMX 
overexpression, we observed that the cells growing in the presence of tetracycline 
(a.k.a. with MDMX overexpression) were more resistant to the TPEN treatment in the 
colony formation assay (Figure II.6C and Figure II.S6C). Together, these results 
indicated that MDMX protects MCF-7 cells from zinc depletion-mediated cell growth 
inhibition. 
Previously it was reported that downregulation of TRPM7 in human cancer cells 
impairs cell proliferation, migration, and invasion (Yee, 2017). As our data suggested 
that TRPM7 actively regulates cellular levels of MDMX, presumably through its 
channel function on intracellular zinc concentration modulation, we reasoned that 
MDMX overexpression might counteract the effect of TRPM7 inhibition on MCF-7 
cells. Consistent with previous reports, depletion of TRPM7 using two different 
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siRNAs led to inhibition of MCF-7 cell growth in a colony formation assay (Figure 
II.6D). However, using MCF-7 cells with tetracycline-inducible MDMX overexpression 
inhibition of TRPM7 with either siRNAs (Figure II.S6D) or NS8593 (Figure II.S6E), we 
did not observe a cell growth difference for the cells with or without MDMX 
overexpression. Similarly, no cell growth difference was observed between MCF-7-
Myc- MDMX cells with stably-expressed Myc-MDMX and MCF-7-pcDNA3 control cells 
(Figure II.S6F and II.S6G). Therefore, under our experimental conditions, MDMX 
overexpression does not rescue TRPM7 inhibition-mediated growth of MCF-7 cells. 
We then assessed MCF-7 cell migration with a wound-scratch assay. As shown 
in Figure II.6E, we found that NS8593 treatment inhibited MCF-7 cell migration. 
Interestingly, MCF-7 cells with stably-expressed MDMX (Figure II.6E) or MCF-7 cells 
with tetracycline-induced MDMX overexpression (Figure II.S6H) were partially 
resistant to this inhibitory effect in comparison to control cells. Similarly, depletion of 
TRPM7 using siRNA inhibited MCF-7 cell migration while MCF-7 cells with stably-
expressed MDMX (Figure II.6F) or MCF-7 cells with tetracycline-induced MDMX 
overexpression (Figure II.S6I) were partially resistant to this inhibitory effect in 
comparison to control cells. Together, our data indicate that TRPM7 may function 







Figure II. 6. MDMX overexpression partially reverses the inhibitory effect of TPEN or 
TRPM7 inhibition on MCF-7 cell migration. (A) TPEN treatment inhibits MCF-7 cell growth 
in a zinc-dependent manner. 5×104 MCF-7 cells were plated on 35 mm dishes. Twenty-four hours 
later, the cells were treated with DMSO, TPEN (5 µM), or TPEN plus ZnSO4 (5 µM each) for 24 
hours. Fresh DMEM medium was then added into each dish and replaced every other day. The 
cells were fixed and stained 5 days after treatment. (B) NSC207895 further inhibits TPEN-
repressed MCF-7 cell proliferation. 1×104 MCF-7 cells were plated on 96-well plates and treated 
in triplicates with DMSO, TPEN (5 µM), NSC207895 (2.5 µM), or TPEN (5 µM) plus NSC207895 
(2.5 µM) for 8 hours. Cell proliferation was measured as described in Materials and Methods. The 
results were expressed as means±s.d. of three independent experiments. (C) MDMX 
overexpression partially rescues the inhibitory effect of TPEN on MCF-7 cells. 5×104 MCF-7 cells 
with tetracycline-inducible MDMX overexpression were plated on 6-well plate with or without 
2.25 µg/ml of tetracycline and treated with DMSO or 5 µM TPEN for 24 hours. Fresh medium was 
then added and replaced every other day. Five days later the cells were fixed and stained. (D) 
Knockdown of TRPM7 inhibits MCF-7 cell growth. MCF-7 cells were treated with control siRNA 
or siRNAs targeting TRPM7 (siTRPM7_1 and siTRPM7_2). Twenty-four hour after transfection, 
2×104 cells were plated in 6-well plate and then fixed and stained 1 week later. (E) MDMX 
overexpression partially rescues cell migration repression mediated by NS8593. MCF-7-pcDNA3 
and MCF- 7-Myc-MDMX cells were plated on 6-well plate to reach ~90% confluence. The cells 
were starved with DMEM plus 0.5% FBS for 24 hours. After that, the cells were scratched and 
incubated in DMEM plus 0.5% FBS with DMSO or NS8593 (30 µM). Images were taken at 0 or 
24 hours after scratch. Percentage of healed wound area at 24 hours related to 0 hour time point 
was graphed. Representative data from one experiment were shown. (F) MDMX overexpression 
partially rescues cell migration repression mediated by TRPM7 ablation. MCF-7-pcDNA3 and 
MCF-7-Myc-MDMX cells were plated on 60 mm dishes for 24 hours and then transfected with 
control siRNA or siRNA targeting TRPM7 (siTRPM7_2). Six hours after transfection, 2×106 cells 
were plated in each well of a 6-well plate to reach ~90% confluence. The cells were starved with 
DMEM plus 0.5% FBS for 24 hours and then scratched. Images were taken and analyzed at 0 or 








Figure II.S 6. MDMX over-expression partially reverses the inhibitory effect of TRPM7 
inhibition on MCF7 cell migration. (A) NSC207895 inhibits MDMX expression in MCF7 cells. 
MCF7 cells were treated with DMSO, TPEN (5 µM), NSC207895 (NSC; 5 µM), or TPEN (5 µM) 
plus increasing dosages of NSC207895 (NSC; 1, 2.5 or 5 µM) for 8 hours. The cells were harvested 
and total cell lysates were prepared and subjected to immunoblotting with anti-MDMX and anti-
actin antibodies. (B) Depletion of MDMX by siRNA further inhibits TPEN-repressed MCF-7 cell 
proliferation. MCF-7 cells were transfected with control siRNA or siRNA targeting MDMX 
(siMDMX). Eighteen hours later, the cells were trypsinized, counted, and plated (6×103 cells for 
each well) on 96-well plates in triplicates. After 24 hours, cells were treated with DMSO or TPEN 
(5 µM). Eight hours later, the medium was removed and replaced with 100 μl of fresh complete 
medium supplemented with 10 μl CellTiter 96® AQueous One Solution. After incubated for 1 
hours at 37°C, the absorbance was measured on an TECAN SPARK Microplate Reader (Tecan) at 
a wavelength of 490 nm. The results were expressed as means±s.d. of three independent 
experiments. (C) Tetracycline induces MDMX expression in MCF7 cells with tetracycline 
inducible MDMX overexpression. MCF7 cells with tetracycline inducible MDMX overexpression 
were plated on 6-well plate with or without 2.25 µg/ml of tetracycline. Twenty-four hours later the 
cells were treated with DMSO or 5 µM TPEN. 5 µM ZnSO4 was added in one of the TPEN-treated 
cells 5 hours later. After another 5 hours incubation, the cells were harvested and total cell lysates 
were analyzed by immunoblotting with indicated antibodies. (D) MDMX overexpression does not 
rescue TRPM7 ablation-mediated cell growth inhibition. 5×104 MCF7 cells with tetracycline 
inducible MDMX overexpression were plated on 6-well plate in triplicates with or without 2.25 
µg/ml of tetracycline. Twenty-four hours later the cells were transfected with control siRNA or 
siRNA targeting TRPM7 (siTRPM7_2). Fresh medium was added 6 hours after treatment and 
replaced every other day. Five days later the cells were fixed and stained with crystal violet (0.05% 
in 20% ethanol). The crystal violet stained cells were scanned using LI-COR Odyssey CLx imaging 
system. The intensity of crystal violet signal in each well was quantified to represent the cell 
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numbers in the well. The absorbance of control siRNA treated cells without addition of tetracycline 
was considered as 100%. (E) TRPM7 inhibitor NS8593 doesn’t affect cell growth for tetracycline 
inducible MDMX overexpression MCF7 cell system. 5×104 MCF7 cells with tetracycline 
inducible MDMX overexpression were plated on 6-well plate per well in triplicates with or without 
2.25 µg/ml of tetracycline in the absence or presence of NS8593 (30 µM). Medium was replaced 
every other day. Five days later the cells were fixed and stained with crystal violet (0.05% in 20% 
ethanol). (F)MCF7-Myc-MDMX cells express higher levels of MDMX in comparison to MCF-
pcDNA3 cells. MCF7- pcDNA3 and MCF7-Myc-MDMX cells were maintained in DMEM with 
250 μg/ml G418. Total cell lysates were prepared and subjected to immunoblotting anti-MDMX 
and anti-actin antibodies. (G) TRPM7 inhibitor NS8593 doesn’t affect cell growth for MDMX 
overexpression stable MCF7 cell system. 5×104 MCF7-pcDNA3 and MCF7-Myc-MDMX cells 
were plated on 6-well plate in triplicates in the absence or presence of NS8593 (30 µM). Medium 
was replaced every other day. Five days later the cells were fixed and stained with crystal violet 
(0.05% in 20% ethanol). (H) MDMX over-expression partially reverses cell migration repression 
mediated by NS8593. MCF7 cells with tetracycline inducible MDMX overexpression were plated 
on 6-well plate with or without 2.25 µg/ml of tetracycline to reach ~90% confluence. The cells 
were starved with DMEM plus 0.5% FBS for 24 hours. After that, they were scratched and 
incubated in DMEM plus 0.5% FBS with DMSO or NS8593 (30 µM). Images were taken at 0 or 
24 hours after scratch. Three different scratched areas were imaged and measured using MRI 
Wound Healing Tool. Percentage of healed wound area at 24 hours related to 0 hour time point 
was graphed. A representative data from one experiment were shown. (I) MDMX over-expression 
partially reverses cell migration repression mediated by TRPM7 knock-down. MCF7 cells with 
tetracycline inducible MDMX overexpression were plated on 60 mm dishes for 24 hours and then 
transfected with control siRNA or siRNA targeting TRPM7 (siTRPM7_2). Six hours after 
transfection both cells were trypsinized and counted. 2×106 cells were plated in each well of a 6-
well plate to reach ~90% confluence. The cells were starved with DMEM plus 0.5% FBS for 24 
hours. After that, they were scratched  and images were taken at 0 or 24 hours after scratch and 





Zinc conducts various biological roles and zinc deficiency has been linked to many 
human diseases, including cancer development. MDMX, a zinc-containing protein and 
crucial negative regulator of p53, is amplified and/or overexpressed in various 
cancers. Here, we report for the first time that zinc depletion such as TPEN treatment 
results in MDMX degradation in a ubiquitination-independent and 20S proteasome-
dependent manner. Moreover, we identified TRPM7, a zinc-permeable ion channel, 
as a novel MDMX-interacting protein. TRPM7 inhibition by siRNAs or channel inhibitor 
NS8593 attenuates while TRPM7 overexpression facilitates the recovery of MDMX 
upon adding back of zinc to TPEN-treated cells. Most importantly, we found that 
TRPM7 inhibition suppresses breast cancer MCF-7 cell migration, which can be 
partially rescued by the overexpression of MDMX. In all, our data indicate that TRPM7 
regulates cellular levels of MDMX in part by modulating intracellular zinc 
concentration. As such our findings with TRPM7 could suggest a therapeutic target 
for combinational cancer treatment. 
In breast cancer patients it has been reported that zinc levels are lower in serum 
but are higher in breast cancer tissue than in normal breast tissue (Grattan & Freake, 
2012). It is intriguing that breast cancer tissue has a significantly high uptake of zinc 
and it is unclear if these changes in serum and tissue zinc concentrations contribute to 
the initiation, promotion, or progression of breast cancer, or whether if they are the 
effects of malignant transformation. We observed that cellular levels of MDMX 
correlate with the intracellular zinc concentration. MDMX overexpression partially 
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rescues the inhibitory effect of zinc depletion on cell growth, indicating that zinc 
deficiency may impose selection pressure for cells with MDMX amplification 
or overexpression during breast cancer development. 
Zinc affects the cellular levels of MDMX at the post-transcriptional level. Since 
MDMX is a zinc-containing protein with two zinc coordination motifs, we anticipated 
that zinc depletion leads to partially unstructured MDMX, which is subjected to 20S 
proteasome-mediated degradation. It is intriguing that MDM2, a well-known E3 
ubiquitin ligase for both p53 and MDMX (Wade et al., 2013) that has also been shown 
to directly interact with the 20S proteasome and facilitate 20S proteasome-mediated 
p53 (Kulikov et al., 2010) or Rb (P. Sdek et al., 2005) degradation, is not involved in zinc 
depletion-mediated MDMX degradation. Since MDM2 and MDMX bind to each other 
through their RING-finger domains, zinc depletion may impair their interaction by 
affecting the RING-finger structure. Further investigation will be needed to test if 
MDMX can bind to 20S proteasome by itself or if other unknown protein(s) are 
required for its 20S proteasome-mediated degradation. 
Zinc transporters, zinc-permeable ion channels, and zinc-sequestering 
metallothioneins have been shown to be critical for intracellular zinc homeostasis. 
Deregulation of their function contributes to tumorigenesis (Kambe, Tsuji, Hashimoto, 
& Itsumura, 2015; Pan et al., 2017). Multiple zinc transporters (such as ZnT2, ZIP6/LIV1, 
ZIP7 and ZIP10), zinc-permeable ion channels (such as TRPC6, TRPM7, and TRPV6), as 
well as metallothionein were reported to be overexpressed in breast cancer, some of 
which are associated with breast cancer metastases and poor prognosis (Inoue, 
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O'Bryant, & Xiong, 2015). Relatedly, TRPM7 is abnormally overexpressed in various 
cancer cells including breast cancer (Yee, 2017) and knockdown of TRPM7 suppresses 
breast cancer cell migration and invasion (Middelbeek et al., 2012). 
We had identified TRPM7 as a novel MDMX interacting protein and found that 
it both stabilizes MDMX and induces changed migration of the MDMX on SDS-PAGE 
when the two proteins are ectopically co-expressed. Although the functional 
importance of this migration change of MDMX remains unknown, we found that the 
channel domain but not the kinase domain is essential for the MDMX migration 
change under our experimental condition. Importantly, we observed that 
overexpression of TRPM7 facilitates but TRPM7 ablation or NS8593 treatment 
inhibits the recovery of cellular levels of MDMX after adding back zinc to TPEN-
treated cells. Therefore, TRPM7 actively regulates cellular levels of MDMX, most 
likely through its zinc permeable channel function. Moreover, we further 
demonstrated that suppression of MCF-7 cell migration upon the inhibition of TRPM7 
can be partially rescued by MDMX overexpression. Based on these findings, we 
speculate that overexpression of TRPM7 in breast cancer cells raises their intracellular 
zinc concentration, which, in turn, increases cellular levels of MDMX to promote 
cancer cell migration. As the cleaved C-terminal kinase domain of TRPM7 has other 
activities in the nucleus (Krapivinsky et al., 2014), it is very likely that other 
mechanism(s) are employed by TRPM7 to promote breast cancer progression. Future 
investigations will be needed to explore those mechanisms. 
TRPM7 is not unique among proteins that are relevant to zinc biology in regards 
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to breast cancer. Other zinc-permeable ion channels, zinc transporters, as well as 
metallothioneins may employ similar mechanisms to influence breast cancer 
development by modulating the cellular levels of zinc and MDMX levels. Indeed, 
when we knocked down ZIP7, a zinc transporter that is overexpressed in breast 
cancer, we observed similarly attenuated MDMX recovery in TPEN-treated MCF-7 
cells upon adding back zinc (Figure II.S7). Therefore, modulating the intracellular 
zinc concentration may be an effective therapeutic strategy for cancer treatment. 
Depending on cellular levels of MDMX and TRPM7 as well as other proteins involved in 
zinc homeostasis, therapeutic strategies and zinc supplementation guidelines have 







Figure II.S 7. Ablation of Zip7 attenuates Zn2+-mediated recovery of MDMX in the presence 
of TPEN. MCF7 cells were treated with control siRNA or siRNA targeting Zip7. Forty-eight hours 
later, cells were treated with 5 µM TPEN for 5 hours and then treated with or without 5 µM ZnSO4 
for another 5 hours. The cells were harvested and total cell lysates were analyzed by 





Cell culture and plasmids 
 
Hek293T, U2OS, and MCF-7 cells were cultured in DMEM medium with 10% FBS 
(Fetal Bovine serum, Gemini Bio-products) and 1% penicillin-streptomycin (Gibco) at 
37°C, 5% CO2. For zinc-deficient DMEM medium, FBS was incubated overnight with 5% 
Chelex 100 (Bio-Rad) before supplemented (10%) into DMEM medium. MCF-7-pcDNA3 
and MCF-7-Myc-MDMX cell lines were constructed by transfecting pcDNA3 or Myc-
MDMX plasmid into MCF-7 cells and then selecting G418 (1mg/ml) resistant clones 
for 2 weeks. Pooled cell clones were maintained in DMEM with 250 μg/ml G418. MCF-
7 with tetracycline-inducible MDMX cell line was obtained from Dr. Xinbin Chen 
(University of California Irvine) and was maintained in DMEM with 4 μg/ml Blasticidin 
and 25 μg/ml Zeocin. U2OS MDMX S367L mutant cells were generated using 
CRISPR/Cas9 genome-editing technology (Cong et al., 2013) as described in 
Supplemental Material. 
HA-p53, Flag-MDM2, Myc-MDMX, and His-Ubiquitin were described previously 
(Zhu et al., 2009). Flag-TRPM7 was a kind gift from Dr. Clapham (Howard Hughes 
Medical Institute). Myc-MDMX variants (S342A, S367L, S403A, and D361A) and Flag-
TRPM7 variants (E1047Q and K1646R) were constructed by site-directed 
mutagenesis. All the mutations were confirmed by Sanger sequencing. 
Antibodies and reagents 
 
Commercially obtained antibodies used were as follows: MDMX (A300-287A, 
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Bethyl; or 8C6, Millipore), actin (C-4, Santa Cruz Biotechnology), Flag (M2, Sigma), HA 
(HA.11, Covance), TRPM7 (A302-700A, Bethyl) and GFP (B-2, Santa Cruz 
Biotechnology). Mouse monoclonal antibodies against human p53 (DO-1) and MDM2 
(3G5, 4B11, 5B10) were used as supernatants from hybridoma cultures. Reagents 
used in this study were as follows: TPEN (N , N , N′, N′-tetrakis (2-pyridinylmethyl) - 1,2-
ethanediamine), MG132, CaCl2, MgCl2, and ZnSO4 from Sigma; NS8593, bispicen, 




Plasmid transfections were performed using PEI (Polysciences; cat# 23966-2) for 
HEK293T cells and Lipofectamine 2000 (Thermo Fisher Scientific) for MCF-7 cells. 
siRNA transfections in MCF-7 cells were performed using Dharmafect 1 (Dharmacon) 
using 50 nM of control siRNA (Allstar negative control siRNA; Qiagen) or siRNA 
targeting TRPM7, MDM2 or Rpn2. The target sequences are: 5’-
TTAATGTATCTACCGTCAGGG-3’ (siTRPM7_1), 5’- GAGTATTTCATGGCAAGAC-3’ 
(siTRMP7_2), 5’-AAGCCATTGCTTTTGAAGTTA-3’ (siMDM2_1), 5’- 
AAGGAATAAGCCCTGCCCA-3’ (siMDM2_2). 5’-GTCTAGATGATCACAAGTA-3’ (siRpn2_1) 
and 5’- GGGTGTAATTCATAAGGGT-3’ (siRpn2_2). 
RNA extraction and quantitative RT-PCR analysis 
 
RNA was extracted using a Qiagen RNeasy mini-kit, and cDNA was synthesized 
with the QuantiTect reverse transcription kit (Qiagen). Samples were analyzed by 
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quantitative real-time PCR on a Bio-Rad CFX 96 using PowerUp SYBR Green (Thermo 
Fisher Scientific). RNA expression was normalized to RPL32 mRNA expression. 
Relative levels were calculated by the comparative Ct method (ΔΔCT method). The 
results are expressed as meanss.d. of four experiments. Primer sequences are: 
RPL32, 5’-TTCCTGGTCCACAACGTCAAG-3’(Forward) and 5’-TGTGAGCGATCTCGGCAC-
3’ (Reverse); MDMX, 5’-GCAAGAAATTTAACTCTCCAAGCAA-3’ (Forward) and 5’-
CTTTGAACAATCTGAATACCAATCCTT-3’ (Reverse). 
In vivo ubiquitination assay 
 
In vivo ubiquitination assays were carried out using a His-Ub construct. After 
cells were harvested, a Ni-NTA pull-down assay was carried out as previously described 
(Zhu et al., 2009). Eluted proteins were analyzed by Western blotting with anti-MDMX 
or anti-p53 antibody. 
Cell proliferation assay 
 
Cell proliferation was measured using the CellTiter 96® AQueous One Solution 
Cell Proliferation Assay (Promega) following manufacturer’s instruction. 1×105 MCF-7 
cells per well were plated in 96-well plates. The cells in triplicates were then treated 
as indicated and the plates were read on a TECAN SPARK Microplate Reader (Tecan) 






Colony formation assay 
 
5104 MCF-7 cells (on 35 mm dishes), MCF-7 with tetracycline inducible MDMX 
overexpression (on 6-well plate with or without 2.25 µg/ml of tetracycline), or MCF-
7 transfected with siRNA targeting TRPM7 (on 6-well plate 6 hours after transfection) 
were plated. The cells were treated with indicated drugs for 24 hours and then fresh 
DMEM medium were added and replaced every other day. Five to seven days after 
treatment the cells were fixed and stained with crystal violet (0.05% in 20% ethanol). 
Wound Healing Assay 
 
About 2×106 cells MCF-7 were plated (for experiments with TRPM7 depletion, 
MCF-7 cells were plated 6 hours after siRNA transfection) to reach ~90% confluence, 
the cells were starved with DMEM plus 0.5% FBS for 24 hours. Then the cells were 
washed twice with 1×PBS, scratched with a 200-µL pipette tip to produce a straight cell-
free “wound”, and washed again with 1×PBS to remove debris followed by addition of 
fresh DMEM plus 0.5% FBS DMEM with DMSO or NS8593 (30 µM) as indicated. Images 
were taken at 0 or 24 hours after scratch using a phase-contrast microscope (Nikon, 
Eclipse Ts2) with 10× magnification. The healing areas were measured using MRI 
Wound Healing Tool (http://dev.mri.cnrs.fr/projects/imagej-
macros/wiki/Wound_Healing_Tool) in Image J. Three different scratched areas 
for each dish/well were imaged and measured. Percentage of healed wound area at 
24 hour related to 0 hour time point was graphed as Percentage of healed area = (area 





Materials and Methods 
 
Cell culture and plasmids 
 
HEK293T cells, PC3 cells and MCF-7 cells were cultured in DMEM medium with 
10% FBS (Fetal Bovine serum, Gemini Bio-products) and 1% penicillin streptomycin 
(Gibco) at 37°C, 5% CO2. LNCaP cells were cultured in RPMI medium with 10% FBS (Fetal 
Bovine serum, Gemini Bio-products) and 1% penicillin streptomycin (Gibco) at 37°C, 5% 
CO2. MCF-7-pcDNA3 and MCF-7-Myc-MDMX cell lines were maintained in DMEM 
with 250 μg/ml G418. MCF-7 with tetracycline inducible MDMX cell line was 
maintained in DMEM with 4 μg/ml Blasticidin and 25 μg/ml Zeocin. 
To establish U2OS MDMX S367L mutant cells, the left (anti-sense; 
GGAAGGTTTCTGAAAGGAAGTAC) and right (sense; CAAATCCTAGGCTAGATCACTGG) 
sgRNAs were cloned into pX335 (Addgene #42335) to cut the genome DNA in the 
intron 10 of mdmx gene. Donor vector was designed to introduce mutation S367L 
(TCG to TTG) in exon 11 of mdmx gene with a FNF selection cassette flanked by left 
and right homologous arms and cloned into pFNF (Addgene #22687). The donor and 
CRISPR plasmids were transfected into U2OS cells, followed by selection with G418 
(800 μg/ml) for 2 to 3 weeks. The resistant clones were expanded and examined for 
FNF insertion on the mdmx locus by PCR. The corrected clones were confirmed by 
both genome and cDNA sequencing. To serve as controls, isogenic wild-type clones 
were also obtained through the same selection process. We obtained two 
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heterozygous (#12, S367L_1; #20, S367L_2) and one homozygous (#23, S367L_3) 
CRISPR cell lines. As the homozygous cell line was somewhat unstable and expressing 
much less MDMX, we only used the two heterozygous cell lines in this study. 
Antibodies and reagents 
 
Antibodies and reagents that were used only in supplemental data section are: 
phosphor-Histone H2A.X (Ser139) (20E3; Cell Signaling Technology); PARP (9542; Cell 
Signaling Technology); LC3B (NB100-2220; Novus); HLI373 (Sigma); Compound 1 
(Sigma); MD-224 (30 nM, MedChem Express); Etoposide (Sigma); Zip7 siRNA (sc-
76962; Santa Cruz Biotechnology); siMDMX (Hs_MDM4_4 FlexiTube siRNA; Qiagen). 
ROS detection assay 
 
2.2 ×104 MCF-7 cells per well were plated in triplicates for 5 experimental groups 
on 96-well plate. Eighteen hours later, two sets of triplicate cells were treated with 
DMSO or TPEN (5 µM) for 8 hours and cellular ROS levels were measured using ROS 
Detection Cell-Based Assay Kit (DCFDA) (item 601520; Cayman Chemical) following 
the manufacture’s procedure. 10 μM of DCFDA was used in the assay for MCF-7 cells. 
Positive control (pyocyanin treatment), negative control (N-actyl cysteine treatment), 
and no treatment control were also included for measurement in triplicates. Total 
DCFDA (2,7-Dichlorofluoroscin Diacetate) fluorescence was measured using an 
excitation wavelength at 480 nm and emission wavelength at 530 nm. 
Purification of MDM2 or MDM2/MDMX Complex and mass spectrometry 
 
HEK293T cells were transfected with Flag-MDM2 or Flag-MDM2 plus Myc-
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MDMX. Potential differential binding partners for MDM2 alone or MDM2/MDMX 
heterodimer were purified and subject to mass spectrometry analysis as 
previously described. Briefly, the HEK293T cells (1 x 10^10) were transfected with a 
Flag-MDM2 or Flag-MDM2 plus Myc-MDMX at a ratio of 10:3. Total cell lysates were 
prepared and subjected to immunoprecipitation with anti-FLAG monoclonal antibody 
(M2)-conjugated beads (Sigma-Aldrich, St. Louis, MO). The beads were washed eight 
times with lysis buffer and then eluted by incubating with 0.2 mg/ml FLAG peptide 
(Sigma-Aldrich) for 2 hrs. The eluate was concentrated and separated on a Tris- Glycine 
gradient gel (4-20%). Proteins on the gel were stained with GelCode Blue (Thermo 
Fischer Scientific, Waltham, MA). Differentially pulled-down protein bands were 
excised, destained with 25 mM ammonium bicarbonate and 50% acetonitrile, dried, 
digested with sequence grade modified trypsin (Promega, Fitchburg, WI) in 50 mM 
Tris-HCl [pH 7.6], extracted with 5% trifluoroacetic acid (TFA), 50% acetonitrile, and 




Chapter III. Detection of cytokine receptors 





Tyramide signal amplification (TSA) is an enzyme-mediated method to enhance 
the immunohistochemical detection of protein, nucleic acid, or other molecules in 
situ. 
Here we describe immunofluorescent detection of a low abundance cytokine 
receptor, interleukin-17 receptor B (IL17RB) in U2OS cells, using tyramide signal 
amplification. In addition, we present a tyramide signal amplification compatible 
double-color immunostaining protocol using primary antibodies from same host 
species. Those applications allow detection of cellular proteins with enhanced 
sensitivity and add flexibility on primary antibody selection in double or multicolor 






Tyramide signal amplification (TSA) utilizes the catalytic activity of 
horseradish peroxidase (HRP) to deposit of a labeled (e.g., fluorophore, biotin, or 
other labeling moieties) tyramide onto target proteins that are previously blotted 
with primary antibody or nucleic acid sequences in-situ. In TSA-based 
immunohistochemical (IHC) or immunofluorescence (IF) detection, activated 
tyramide forms covalent bonds with tyrosine residues on the target protein, 
resulting in permanent high density labeling. The signals can then be detected by 
standard chromogenic or fluorescent techniques. As this technique is based on 
detection via indirect immunostaining involving primary and secondary antibodies, 
TSA  promotes enhanced sensitivity and high specificity for target protein detection, 
especially for those low abundance proteins. 
Double or multicolor immunofluoresence staining is useful to examine the 
distribution of two (or more) different antigens in the same sample of cells. It requires 
unlabeled primary antibodies from different hosts or different fluorescently 
labeled primary antibodies for different antigens. The availability of primary 
antibodies restricts the usage of the application. TSA-based covalently  linked 
labeling can preserve antigen-associated signal even after serial stripping of the 
primary/secondary antibody pairs, making this process amenable to multiple 
rounds of staining in a sequential fashion (Hunyady, Krempels, Harta, & Mezey, 1996; 
Parra et al., 2017; Stack, Wang, Roman, & Hoyt, 2014). Most importantly, 
immunostaining with tyramide signal amplification allows double or multicolor 
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immunofluoresence staining being performed using unlabeled primary antibodies 
from same hosts without the concern for crosstalk. This will add flexibility on 
the primary antibody selection and facilitate multiplex staining design. 
Il17RB is a cytokine receptor that binds to interleukin 17 (IL-17) cytokine family 
members IL-17B and IL-17E (IL-25) (Monin & Gaffen, 2018). It has been detected in 
kidney, pancreas, liver, brain, and intestine (Kolls & Linden, 2004). Amplification of IL-
17B/RB signaling has been linked to tumorigenesis in breast (Alinejad, Dolati, 
Motallebnezhad, & Yousefi, 2017), gastric (Bie et al., 2017), pancreatic (Wu et al., 
2015), and thyroid (Ren, Xu, Liu, Wang, & Qin, 2017) cancers. We have observed that 
low levels of IL17RB expression in using tyramide signal amplification for 
immunofluorescence (Figure III.1). In addition, we describe a tyramide signal 
amplification compatible double-color immunostaining protocol using primary 

















Figure III. 1. Tyramide signal amplification allows the detection of low abundance cytokine 
receptor IL17RB. Immunofluorescence staining of IL17RB in U2OS cells with goat anti-rabbit 
IgG (H+L) Alexa Fluor™ 594 secondary antibody. Immunofluorescence staining of IL17RB in 














Figure III. 2. Tyramide signal amplification allows the double-color immunostaining of 
IL17RB and p53 using primary antibodies from the same host species. IL17RB in U2OS cells 
was stained with Alexa Fluor™ 594 Tyramide SuperBoost™ Kit, goat anti-rabbit IgG followed by 
immunostaining of p53 with goat anti- rabbit IgG (H+L) Alexa Fluor™ 488 secondary antibody. 









1. Human osteosarcoma U2OS cells. 
2. DMEM complete medium: Dulbecco's Modified Eagle Medium supplemented with 
10% Fetal Bovine Serum and 100 µg/mL penicillin/streptomycin. 
3. 1X Phosphate-buffered Saline (PBS, pH 7.2): 140 mM NaCl, 2.6 mM KCl, 2 mM 
Na2HPO4, 1.45 mM KH2PO4. 
4. 4% paraformaldehyde in 1X PBS (see Note 1). 
5. Alexa Fluor™ 594 Tyramide SuperBoost™ Kit, goat anti-rabbit IgG (see Note 2). 
6. Antibodies: anti-p53 (FL393; Santa Cruz); anti-IL17RB (NBP2-43767; Novus); Goat 
anti- rabbit IgG (H+L) Alexa Fluor™ 594 secondary antibody; Goat anti-rabbit IgG 
(H+L) Alexa Fluor™ 488 secondary antibody. 
7. Blocking buffer: 0.5% BSA in 1X PBS. 
8. Permeabilization buffer: 0.5% Triton X-100 in 1X PBS. 
9. 10 mM sodium citrate (pH 6.0): fleshly made from 1 M sodium citrate (pH 6.0) stock. 
10. 5 mg/mL DAPI in DMSO. 
11. Fluorescence microscope (Nikon Eclipse Ti2). 
12. Cell culture dishes: diameter 35 mm. 
13. Cover slides: 22 x 22mm. 
14. Microscope slides: 75 x 25mm. 
15. Microwave-safe container: about 76 x 150 mm (see Note 3). 
16. Microwave. 













Immunofluorescent staining with tyramide signal amplification 
 
1. Perform cell culture procedures in biosafety cabinets using sterile equipment and 
pre-warmed (37 ºC) reagents.   
2. The day before immunostaining, place sterile glass coverslips in each 35 mm cell 
culture dish using sterile forceps. 
3. Seed 6 x 105 U2OS cells into each 35 mm dish with glass coverslips. 
4. Incubate the cells with 2 ml DMEM in a 37 ºC CO2 incubator. 
5. On the second day, aspirate the DMEM medium from the dish and wash the cells 
twice with 1 ml 1X PBS at room temperature. 
6. Fix cells with 1 ml 4% paraformaldehyde in 1X PBS, at room temperature for 20 
minutes. 
7. Wash the cells with 1X PBS. 
8. Permeabilize the cells with permeabilization buffer at room temperature for 90 
seconds. 
9. Wash the cells with 1X PBS. 
10. Block the cells with blocking buffer at room temperature for 20-30 minutes. 
11. Incubate the cells with the 100 ul anti-IL17RB antibody (1:500 dilution in blocking 
buffer) at room temperature for 1 hour (see Note 4). 
12. Wash the cells 3 times with 1X PBS. 
13. Incubate the cells with the anti-rabbit second antibody with HRP at room 
temperature for 2 hours (see Note 5). 
14. Wash the cells 3 times with 1X PBS. 
15. Prepare the following solutions during washing (see Note 6):   
a. 100X H2O2: one drop (50µL) of stock (3%) to 1 ml distilled water 
b. 1X Reaction Buffer (RB): one drop of stock to 1 ml distilled water 
c. Stop solution: 1:11 dilution in 1X PBS (10 ul stock in 100 ul 1X PBS) 
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16. Prepare the tyramide solution by mixing 100 ul of 1XRB + 1 ul of 100XH2O2 + 1 
ul of Tyramide stock (see Note 7). Mix the solution by briefly vortexing. 
17. Add the tyramide solution to the cells on and incubate them in the dark for 5 
minutes (see Note 8). 
18. Add the 100 ul stop solution to the cells and wash them using 1X PBS. 
19. Counter stain cells with 0.5 µg/mL DAPI (freshly diluted in 1X PBS) for 1 minutes. 
20. Wash the cells 3 times using 1X PBS. 
21. Mount the cover slip onto a frosted microscope slide preloaded with 9 ul cold 
50% glycerol. 
22. Seal the cover slips with nail polish (fix the corners first and then spread it to all 
the edges). 
23. Incubate for 15 min at room temperature in the dark to allow the nail polish to dry. 
24. Store the cover slips in a dark place at 4°C in a slide box. 
25. Double-color immunofluorescent staining with tyramide signal amplification 
 
Double-color immunofluorescent staining with tyramide signal 
amplification 
 
1. Perform procedures as in section 3.1, steps 1-17 to immunostain IL17RB with 
tyramide signal amplification. 
2. Wash the cells 3 times using 1X PBS. 
3. Aliquot 40 ml sodium citrate into a microwave-safe container and microwave 
at Hi power for 1 minute with cap on (see Note 9). 
4. Take out the cover glass from 35 mm dish with thin-tipped forceps, place it (the cell 
side up) in the heated the sodium citrate solution, and microwave at Hi power for 30 
seconds (see Note 10). 
5. Take out the cover glass from the container and put it back into 35 mm dish with 1X 
PBS. 
6. Wash the cells 3 times with 1X PBS. 
7. Block the cells with blocking buffer at room temperature for 20-30 minutes. 
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8. Incubate the cells with the 100 ul anti-p53 antibody (1:500 dilution in blocking 
buffer) at room temperature for 1 hour in the dark. 
9. Wash the cells 3 times with 1X PBS. 
10. Incubate the cells with the100 ul goat anti-rabbit IgG (H+L) Alexa Fluor™ 488 
secondary antibody (1:200 dilution in blocking buffer) at room temperature for 1 
hour in the dark. 
11. Wash the cells 3 times with 1X PBS. 
12. Counter stain them with 0.5 µg/mL DAPI (freshly diluted in 1X PBS) for 1 minutes. 
13. Wash the cells 3 times using 1X PBS. 
14. Mount the cover slip onto a frosted microscope slide preloaded with 9 ul cold 
50% glycerol (see Note 11). 
15. Seal the cover slips with nail polish (fix the corners first and then spread it to all 
the edges). 
16. Incubate for 15 min at room temperature in the dark to allow the nail polish to dry. 
17. Store the cover slips in a dark place at 4°C in a slide box. 
 
Fluorescence microscopy   
 
1. Place the microscope slides containing coverslips (with the coverslips facing down) 
on the Nikon Eclipse Ti2 fluorescence microscope.   
2. Obtain all images with a 50X fluorescent oil objective using 470 (green), 590 (red), 
and DAPI (blue) channels.   
3. Adjust the exposure time and light intensity to obtain an optimum contrast between 
the signal and the background fluorescence. Use the same setting to take images 
for all the slides (see Note 12). 
 
 
Notes   
 
1. Paraformaldehyde is toxic and hard to dissolve. To make 4% paraformaldehyde  50 
mL in 1X PBS: 
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a. Add 2 g of paraformaldehyde to 40 mL 65°C ddH2O. 
b. Add 150µL of 1M NaOH (or 30µL of 5 M NaOH) to help 
paraformaldehyde dissolve faster. Mix the solution until it is clear and 
all the paraformaldehyde has dissolved   
c. Add 5 mL of 10X PBS. 
d. Adjust the pH of solution using 1M HCl to 7.2 
e. Add ddH2O to bring the volume to 50 mL. 
f. Filter the solution using 45 um filter. The solution can be store at 4°C 
for up to 3 days. For long term storage, an aliquot of the solution should 
be kept at -20°C. 
2. There are tyramide signal amplification from different vendors. SuperBoost kit is 
used in the present protocol because it has 2-10 times greater sensitivity than 
regular tyramide amplification techniques. Depending on the availability of antibody 
and choice of Alex Fluor dye, different kit can be used. In kit it contains 1X blocking 
buffer, 1X poly-HRP-conjugated secondary antibody, Alexa Fluor tyramide 
reagent, stabilized 3% hydrogen peroxide   solution, 20X reaction buffer, reaction 
stop solution, and dimethylsulfoxide (DMSO). Please see manufacturer's brochure 
for details.  
3. Any microwave-safe container can be used. Based on the size of container, the 
volume of sodium citrate and microwave time need to be adjusted to make sure that 
the sodium citrate buffer is boiled and the cover glass is immersed in the buffer all 
the time. 
4. Depending on the primary antibody used, 1 hour room temperature or 4°C overnight 
primary antibody incubation can be performed. For overnight incubation, a 
humidified chamber such as a covered box with damp paper towel is needed to avoid 
sample dry out. 
5. Anti-rabbit second antibody with poly-HRP from the SuperBoost kit is used here. In 
this system, several HRP enzymes are conjugated with short polymers to enhance 
the signal over regular HRP system. The optimal incubation time is 2 hours but it can 
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be adjusted to achieve the best specific signal/background signal ratio. 
6. 100X H2O2, 1X Reaction buffer, and Stop solution need to be prepared fresh. The 
reaction stop reagent stock solution is prepared according to manufactures’ 
instruction and stored at -20°C.  
7. 100X Tyramide stock solution: the Alexa Fluor tyramide reagent is dissolved in DMSO 
according to manufactures’ instruction and stored at 4°C in dark. Depending on the 
choice of Alex Fluor dye, a SuperBoost kit with a specific Alexa Fluor tyramide reagent 
is needed. 
8. Incubation time can be adjusted to achieve the best specific signal/background signal 
ratio. Five minutes incubation works for most of the applications in our hand. 
9. For a microwave safe container with size about 76 x 150 mm, 40 mL sodium citrate 
is optimal for the application. Based on the container used, the volume of sodium 
citrate need to be adjusted. In addition, since different microwave oven models have 
different power setting, the microwaving time need to be adjusted accordingly. The 
sodium citrate buffer need to be boiled before putting in the coverslip. The coverslip 
need to be immersed in the buffer all the time during the microwaving. 
10. The microwaving time need to be adjusted depending on different microwave oven 
models to keep the buffer in boil but not dry. For tissue samples, it has been 
suggested to place the sample in citrate buffer and heat with 100% power until 
boiling and then reduce the power to 20% and keep microwaving for additional 15 
minutes. 
11. A mountant with antifade properties is preferred but cold 50% glycerol is OK for 
normal use. 
12. Depending on the signal observed from fluorescence microscopy, adjustment can be 
made for immunostaining steps. If there is low signal, primary antibody dilution and 
incubation time can be optimized. Also, the incubation time with tyramide reagent 
for step 3.1.17 can be lengthened.  If there is excess signal, primary antibody dilution 
and incubation time can be optimized. In addition, the incubation time with tyramide 
reagent for step 3.1.17 can be shortened and the working concentration of tyramide 
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reagent can be decreased. If there is high background, primary antibody dilution and 
incubation time can be optimized. Also, the concentration of secondary antibody can 
be decreased and incubation time with tyramide reagent for step 3.1.17 can be 
shortened. Include a primary antibody only and a second antibody only staining 
control can help on which action is needed to optimize the staining condition. Here, 
staining of a transfected protein (Flag-TRPM7-KR) is carried out with staining controls 
to optimize the condition. This protein is normally weakly stained with standard 








Figure III. 3. Optimizing staining condition for tyramide signal amplification using a 
transfected protein. U2OS cells were transfected with Flag-TRPM7-KR or empty vector pcDNA3 
and then subjected to immunostaining using anti-Flag antibody with goat anti-rabbit IgG (H+L) 




Chapter IV. Future Direction 
 
Despite our data shown in Chapter II indicates MDMX is degraded by 20S 
proteasome in a ubiquitin-independent manner upon zinc-depletion treatment, more 
experiments need to be carried out to determine the detail mechanism. First, it would 
be intriguing to know how MDMX is delivered to 20S proteasome. In order to be 
degraded by proteolytic enzymes locating in inner rings of 20S proteasome, 
substrates have to be recognized by alpha subunits on outer rings. Although MDM2 
has been shown to direct p21 and Rb to 20S proteasome independent of 
ubiquitination through its interaction with 20S subunit alpha 7, it may not be involved 
in 20S proteasome-mediated MDMX degradation. We have showed that MDM2 
depletion by siRNA or MDM2 PROTAC degrader doesn’t rescue TPEN-induced MDMX 
reduction. To support our conclusion, we will further examine the involvement of 
MDM2 using MEF cells with or without mdm2 deletion. In addition, we will explore 
the hypothesis that MDMX directly interacts with 20S proteasome. Since MDM2 and 
MDMX share high homologue and it has been shown that the Ring domain of MDM2 
is required for 20S subunit- substrate interaction, it is possible that MDMX can also 
directly interact with 20S proteasome subunits. Immunoprecipitation of different 20S 
proteasome subunits and MDMX will be carried out to test the hypothesis. 
Alternatively, an unknown protein(s) facilitates the interaction between MDMX and 
20S proteasome. Proteomic analysis of MDMX binding proteins in the presence of 
TPEN and MG132 may give answers for that. 
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We have observed that TRPM7 overexpression leads to a migration change of 
MDMX on SDS-PAGE. It will be interesting to know if this is due to the post-translational 
modifications of MDMX and how TRPM7 is involved. As a bi-functional enzyme, 
cleaved c-terminal domain of TRPM7 has been shown to phosphorylate several 
proteins including histones. It will be worth to test if TRPM7 can target MDMX for 
phosphorylation. In addition, it has been shown that TRPM7 often forms heterodimer 
with TRPM6 for its function. We will further examine if TRPM6 also participates in 
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